4/15/2024 | SP | New Issue: Citi sells $1.1 million contingent coupon market-linked autocalls on three stocks
|
4/11/2024 | SP | New Issue: UBS prices $695,000 return optimization securities linked to Pfizer
|
4/10/2024 | SP | New Issue: UBS prices $5.52 million trigger autocallable contingent yield notes on Pfizer
|
4/9/2024 | SP | New Issue: Citigroup prices $2.87 million contingent coupon equity linked autocalls tied to Pfizer
|
3/26/2024 | SP | New Issue: BMO sells $4.64 million autocallable barrier notes with contingent coupon on Pfizer
|
3/19/2024 | SP | New Issue: HSBC prices $10 million buffered contingent income autocalls with memory on Pfizer
|
3/19/2024 | SP | New Issue: HSBC prices $20 million buffered contingent income autocalls with memory on Pfizer
|
3/15/2024 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Pfizer
|
3/12/2024 | SP | New Issue: UBS prices $205,000 trigger phoenix autocallables linked to Pfizer
|
3/11/2024 | SP | New Issue: UBS prices $11.93 million contingent income autocallable securities on Pfizer
|
3/10/2024 | SP | New Issue: BMO sells $4.14 million autocallable barrier notes with contingent coupon on Pfizer
|
3/7/2024 | SP | New Issue: RBC prices $2 million notes linked to basket of 10 equal stocks
|
3/4/2024 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Pfizer
|
2/28/2024 | SP | New Issue: Citigroup prices $812,000 autocallable contingent coupon notes on stocks
|
2/23/2024 | SP | New Issue: Citigroup prices $725,000 18.25% callable contingent coupon equity notes on stocks
|
2/23/2024 | SP | New Issue: Citigroup prices $775,000 20% callable contingent coupon equity notes on stocks
|
2/15/2024 | SP | New Issue: UBS prices $257,000 trigger return optimization securities on Pfizer
|
2/12/2024 | SP | New Issue: UBS prices $3.4 million 8.6% trigger callable yield notes on two stocks
|
2/9/2024 | SP | New Issue: RBC prices $3.64 million notes linked to basket of 10 equal stocks
|
2/2/2024 | SP | New Issue: Morgan Stanley prices $1.43 million callable contingent income securities tied to Pfizer
|
2/2/2024 | SP | New Issue: HSBC prices $2.05 million autocallable contingent income barrier notes linked to Pfizer
|
2/1/2024 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Pfizer
|
1/31/2024 | SP | New Issue: JPMorgan prices $310,000 capped notes linked to Pfizer
|
1/26/2024 | SP | New Issue: UBS prices $300,000 trigger phoenix autocallables linked to Pfizer
|
1/24/2024 | SP | New Issue: Citigroup prices $1.4 million contingent coupon equity linked autocalls on Pfizer
|
1/24/2024 | SP | New Issue: Citigroup prices $7.49 million contingent coupon equity linked autocalls on Pfizer
|
1/3/2024 | SP | New Issue: JPMorgan sells $1.55 million contingent market-linked securities on Pfizer
|
1/3/2024 | SP | New Issue: Scotia prices $6.37 million of trigger autocallable contingent yield notes on Pfizer
|
12/19/2023 | SP | New Issue: Citi prices $1.1 million callable contingent coupon equity notes on Pfizer
|
12/14/2023 | SP | New Issue: Barclays sells $1 million trigger autocallable contingent yield notes on Pfizer
|
12/13/2023 | BKGNIG | S&P lowers Pfizer
|
12/13/2023 | BKGNIG | Moody’s prunes Pfizer
|
12/6/2023 | SP | New Issue: UBS prices $3.48 million barrier market-linked notes with daily observation on Pfizer
|
12/5/2023 | SP | New Issue: RBC prices $2.45 million notes linked to an equal basket of 10 stocks
|
12/5/2023 | SP | New Issue: RBC prices $1.24 million autocallable contingent coupon barrier notes with memory on Pfizer
|
12/1/2023 | SP | New Issue: Barclays prices $250,000 callable contingent coupon notes on Pfizer
|
11/30/2023 | SP | New Issue: Citigroup prices $1.39 million contingent coupon equity linked autocalls tied to Pfizer
|
11/29/2023 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Pfizer
|
11/27/2023 | SP | New Issue: HSBC sells $445,000 income plus notes with potential 8.5% coupon on five stocks
|
11/27/2023 | SP | New Issue: HSBC sells $375,000 income plus notes on stock basket
|
11/27/2023 | SP | New Issue: Morgan Stanley prices $1.2 million contingent income autocallables linked to Pfizer
|
11/27/2023 | SP | New Issue: Citigroup prices $1.14 million 12.2% autocallable contingent coupon notes on Pfizer
|
11/20/2023 | SP | New Issue: HSBC prices $3.61 million autocallable contingent income barrier notes with memory
|
11/16/2023 | SP | New Issue: JPMorgan prices $1 million capped accelerated barrier notes linked to Pfizer
|
11/10/2023 | SP | New Issue: UBS prices $4.91 million trigger yield notes linked to S&P, Pfizer
|
11/1/2023 | BKBWEMGNIG | Pfizer revenues fall significantly; Covid products see sharp decline
|
10/31/2023 | SP | New Issue: UBS sells $1.52 million trigger autocallable contingent yield notes with memory on stocks
|
10/27/2023 | SP | New Issue: UBS sells $5.2 million trigger autocallable contingent yield notes with memory on stocks
|
10/17/2023 | GNIG | S&P changes Pfizer outlook to negative
|
10/12/2023 | SP | New Issue: UBS prices $1.16 million 9.35% airbag autocallable yield notes linked to Pfizer
|
10/5/2023 | SP | New Issue: RBC prices $1.05 million trigger autocallable contingent yield notes on Pfizer
|
10/2/2023 | SP | New Issue: BMO sells $1.92 million autocallable barrier notes with contingent coupon on Pfizer
|
9/22/2023 | SP | New Issue: GS Finance prices $806,000 callable contingent coupon equity notes on Pfizer
|
9/14/2023 | SP | New Issue: RBC prices $3.41 million notes linked to an equal basket of 10 stocks
|
9/14/2023 | SP | New Issue: Citigroup prices $10.05 million contingent income autocallables linked to Pfizer
|
9/13/2023 | SP | New Issue: Morgan Stanley sells $2.21 million contingent market-linked memory autocalls on stocks
|
9/5/2023 | SP | New Issue: UBS prices $4.57 million trigger autocallable contingent yield notes on Pfizer
|
8/16/2023 | SP | New Issue: JPMorgan prices $1.98 million autocallable accelerated barrier notes linked to Pfizer
|
8/14/2023 | SP | New Issue: BMO sells $2.02 million autocallable barrier notes with contingent coupon on Pfizer
|
7/9/2023 | SP | New Issue: Citi prices $500,000 9.15% autocallable contingent coupon notes on Pfizer
|
6/22/2023 | SP | New Issue: CIBC sells $1.69 million 8.532% fixed interest barrier notes on Pfizer, Russell
|
6/13/2023 | SP | New Issue: HSBC sells $156,000 income plus notes with 6% potential coupon on stock basket
|
6/7/2023 | SP | New Issue: JPMorgan prices $3.09 million autocallable contingent interest notes on three stocks
|
6/5/2023 | SP | New Issue: JPMorgan sells $3.09 million autocallable contingent interest notes on three stocks
|
5/23/2023 | SP | New Issue: RBC prices $388,000 autocallable contingent coupon barrier notes on Pfizer
|
5/19/2023 | IG | Market Commentary: Lighter IG issuance eyed as market digests week’s $62 billion of deals; ETF inflows up
|
5/18/2023 | SP | New Issue: Citigroup prices $600,000 17.65% callable contingent coupon equity notes on stocks
|
5/17/2023 | EMIG | New Issue: Pfizer unit details $31 billion notes in eight tranches for Seagen acquisition
|
5/16/2023 | EMIG | New Issue: Pfizer unit prices $31 billion notes in eight tranches for Seagen acquisition
|
5/15/2023 | EMGNIG | S&P assigns Pfizer notes A+
|
5/15/2023 | EMGNIG | Moody’s rates Pfizer notes A1
|
5/15/2023 | EMIG | Pfizer unit to issue eight tranches of notes for Seagen acquisition
|
5/1/2023 | SP | New Issue: GS prices $200,000 contingent coupon autocallables linked to Pfizer
|
4/13/2023 | SP | New Issue: HSBC sells $90,000 income plus notes with 7.5% potential coupon on stock basket
|
4/11/2023 | SP | New Issue: HSBC sells $220,000 income plus notes with 6.5% potential coupon on stock basket
|
4/10/2023 | SP | New Issue: HSBC sells $1.25 million yield notes on Pfizer, Chubb
|
3/27/2023 | SP | New Issue: JPMorgan sells $1.46 million autocallable contingent interest notes on Pfizer
|
3/18/2023 | SP | New Issue: UBS sells $750,000 trigger autocallable contingent yield notes on pharma stocks
|
3/18/2023 | SP | New Issue: HSBC sells $290,000 income plus notes with 7% potential coupon on stock basket
|
3/17/2023 | SP | New Issue: JPMorgan prices $1 million digital equity notes linked to Pfizer
|
3/15/2023 | GNIG | Fitch changes Pfizer outlook to stable
|
3/13/2023 | GNIG | Moody’s revises Pfizer view to negative
|
3/13/2023 | BKBWGNIG | Pfizer expects unchanged IG ratings from $31 billion acquisition debt
|
2/27/2023 | SP | New Issue: HSBC sells $6 million contingent income autocalls on two pharma stocks
|
2/27/2023 | SP | New Issue: HSBC sells $1.17 million autocallable contingent income barrier notes on Pfizer
|
2/9/2023 | SP | New Issue: Citi prices $1.17 million contingent coupon equity linked autocallables on Pfizer
|
1/26/2023 | SP | New Issue: RBC prices $3 million trigger autocallable contingent yield notes on Pfizer
|
1/4/2023 | SP | New Issue: TD sells $1.67 million 14.5% autocallable fixed-interest barrier notes on four stocks
|
12/28/2022 | SP | New Issue: RBC prices $75,000 autocallable contingent coupon barrier notes on Pfizer
|
12/28/2022 | SP | New Issue: UBS prices $300,000 trigger phoenix autocallables linked to Pfizer
|
12/28/2022 | SP | New Issue: UBS prices $245,000 trigger phoenix autocallables linked to Pfizer
|
12/20/2022 | SP | New Issue: HSBC sells $2.76 million income plus notes with 7% potential coupon on stock basket
|
11/21/2022 | GNIG | Moody's pumps up Pfizer
|
11/1/2022 | SP | New Issue: JPMorgan prices $410,000 12.05% autocallable contingent interest notes tied to Pfizer
|
9/26/2022 | GNIG | Fitch changes Pfizer view
|
9/26/2022 | SP | New Issue: UBS prices $2.92 million trigger autocallable contingent yield notes on Pfizer
|
9/21/2022 | SP | New Issue: JPMorgan sells $9.5 million trigger autocallable contingent yield notes on Pfizer
|
9/13/2022 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallables linked to Pfizer
|
9/2/2022 | SP | New Issue: RBC sells $750,000 autocallable contingent coupon barrier notes on Pfizer
|
8/14/2022 | SP | New Issue: BMO sells $1.26 million callable notes with contingent coupon on Pfizer
|
7/28/2022 | SP | New Issue: UBS prices $525,000 trigger phoenix autocallables linked to Pfizer
|
7/26/2022 | SP | New Issue: UBS prices $2.06 million trigger autocallable contingent yield notes on four stocks
|
7/21/2022 | SP | New Issue: UBS prices $127,000 buffered return optimization securities on Pfizer
|
6/25/2022 | SP | New Issue: CIBC sells $1.19 million contingent coupon autocallable barrier notes on three stocks
|
6/23/2022 | SP | New Issue: Credit Suisse sells $500,000 contingent coupon autocallable yield notes on four stocks
|
6/9/2022 | SP | New Issue: UBS prices $5.24 million contingent income autocalls on three stocks
|
6/8/2022 | SP | New Issue: JPMorgan prices $750,000 autocallable contingent interest notes on pharma stocks
|
5/16/2022 | SP | New Issue: HSBC sells $526,000 callable contingent income barrier notes on four stocks
|
5/10/2022 | SP | New Issue: UBS prices $2.29 million trigger autocallable contingent yield notes on Pfizer
|
5/3/2022 | SP | New Issue: JPMorgan sells $340,000 contingent interest autocalls on pharma stocks
|
4/26/2022 | SP | New Issue: Credit Suisse sells $1.75 million accelerated barrier notes on basket
|
4/22/2022 | SP | New Issue: JPMorgan prices $1.61 million trigger autocallable gears linked to Pfizer
|
4/21/2022 | SP | New Issue: Morgan Stanley prices $7.1 million contingent income autocallables linked to Pfizer
|
4/21/2022 | SP | New Issue: UBS prices $140,000 trigger phoenix autocallables linked to Pfizer
|
2/9/2022 | SP | New Issue: Morgan Stanley prices $1.5 million contingent income autocalls linked to Chevron, Pfizer
|
2/9/2022 | SP | New Issue: Morgan Stanley sells $5.13 million trigger autocallable contingent yield notes on Pfizer
|
2/3/2022 | SP | New Issue: UBS sells $2.82 million 7.3% airbag autocallable yield notes on Pfizer
|
1/31/2022 | SP | New Issue: RBC prices $2.19 million autocallable contingent coupon barrier notes on Pfizer
|
1/25/2022 | SP | New Issue: HSBC sells $7.55 million 8.6% airbag autocallable yield notes on Pfizer
|
1/20/2022 | SP | New Issue: RBC prices $4.61 million autocallable contingent coupon barrier notes on Pfizer
|
1/7/2022 | SP | New Issue: UBS prices $2.68 million trigger autocallable contingent yield notes on stocks, ETF
|
1/7/2022 | SP | New Issue: JPMorgan sells $3.35 million autocallable contingent interest notes on Pfizer
|
12/17/2021 | SP | New Issue: Credit Suisse sells $3.83 million contingent coupon autocallable yield notes on stocks
|
12/14/2021 | GNIG | Moody's alters Pfizer view to positive
|
11/22/2021 | SP | New Issue: Barclays prices $567,000 notes linked to Pfizer, Boston Scientific, Intellia
|
10/20/2021 | SP | New Issue: UBS prices $2.74 million trigger autocallable contingent yield notes on Pfizer
|
10/14/2021 | GNIG | Fitch stabilizes Pfizer view
|
9/16/2021 | SP | New Issue: Citi sells $5.21 million callable contingent coupon equity notes on three stocks
|
8/30/2021 | SP | New Issue: UBS prices $500,000 trigger phoenix autocallables linked to Pfizer
|
8/21/2021 | SP | New Issue: Credit Suisse sells $8.78 million autocallable contingent income securities on pharma stocks
|
8/16/2021 | GNIG | New Issue: Pfizer sells $1 billion 1.75% 10-year notes at Treasuries plus 53 bps
|
8/16/2021 | BKGNIG | S&P rates Pfizer notes A+
|
8/16/2021 | BKGNIG | Moody's assigns A2 to Pfizer notes
|
8/16/2021 | GNIG | Pfizer to sell green senior notes due 2031 via four bookrunners
|
8/2/2021 | SP | New Issue: Credit Suisse sells $3.87 million contingent income autocalls on two stocks
|
7/6/2021 | SP | New Issue: Credit Suisse sells $20.64 million contingent income autcallables on Moderna, Pfizer
|
6/22/2021 | SP | New Issue: UBS prices $5.07 million contingent income autocalls on pharma stocks
|
5/19/2021 | SP | New Issue: Credit Suisse sells $625,000 contingent coupon autocallable yield notes on four stocks
|
4/19/2021 | SP | New Issue: TD Bank prices $2.04 million of autocallable contingent interest barrier notes on stocks
|
4/16/2021 | SP | New Issue: Credit Suisse sells $1.99 million autocallable contingent coupon notes on pharma stocks
|
4/15/2021 | SP | New Issue: UBS sells $8.57 million trigger autocallable contingent yield notes on Pfizer
|
3/21/2021 | SP | New Issue: Credit Suisse sells $6.59 million autocallable contingent income notes on pharma stocks
|
3/15/2021 | SP | New Issue: UBS prices $5 million trigger autocallable contingent yield notes on stock basket
|
3/11/2021 | SP | New Issue: UBS prices $15.4 million trigger autocallable contingent yield notes on stock basket
|
3/5/2021 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Pfizer
|
2/25/2021 | SP | New Issue: UBS sells $15.4 million contingent yield trigger autocallables on stock basket
|
2/17/2021 | SPSW | Structured products issuance at $1.29 billion for month as market rallies, volatility high
|
2/10/2021 | SP | New Issue: UBS prices $400,000 trigger phoenix autocallables linked to Pfizer
|
2/9/2021 | SP | New Issue: Credit Suisse sells $1.4 million contingent coupon autocallables on pharma stocks
|
2/5/2021 | SP | New Issue: JPMorgan prices $1.55 million callable contingent interest notes linked to Pfizer
|
1/30/2021 | SP | New Issue: JPMorgan prices $1 million callable contingent interest notes linked to Pfizer
|
1/30/2021 | SP | New Issue: Credit Suisse sells $3.45 million contingent coupon autocallable yield notes on pharma stocks
|
1/4/2021 | SP | New Issue: Credit Suisse sells $1.56 million contingent coupon autocallable reverse converts on stocks
|
1/4/2021 | SP | New Issue: Credit Suisse sells $1.22 million contingent coupon autocallable reverse converts on stocks
|
1/4/2021 | SP | New Issue: RBC prices $9.91 million autocallable contingent coupon barrier notes on Pfizer
|
12/31/2020 | SP | New Issue: Credit Suisse sells $12.23 million contingent income autocalls on two pharma stocks
|
12/31/2020 | SP | New Issue: UBS prices $10 million buffered income autocallables tied to Pfizer
|
12/28/2020 | SP | New Issue: UBS prices $125,000 contingent absolute return autocallables linked to Pfizer
|
12/28/2020 | SP | New Issue: UBS prices $545,000 contingent absolute return autocallables linked to Pfizer
|
12/28/2020 | SP | New Issue: UBS prices $655,000 trigger phoenix autocallables linked to Pfizer
|
12/28/2020 | SP | New Issue: UBS prices $290,000 trigger phoenix autocallables linked to Pfizer
|
12/28/2020 | SP | New Issue: UBS prices $830,000 trigger phoenix autocallables linked to Pfizer
|
12/27/2020 | SP | New Issue: UBS sells $5 million trigger autocallable contingent yield notes on basket of stocks
|
12/27/2020 | SP | New Issue: BofA prices $1.15 million contingent income autocallable yield notes on Pfizer
|
12/26/2020 | SP | New Issue: Citi sells $300,000 autocallable contingent coupon equity notes on four stocks
|
12/19/2020 | SP | New Issue: CIBC sells $625,000 contingent coupon autocallable notes on stocks
|
12/19/2020 | SP | New Issue: Citi sells $1.79 million autocallable contingent coupon equity notes on stocks
|
12/17/2020 | SP | New Issue: HSBC sells $8.71 million 7.05% airbag autocallable yield notes on Pfizer
|
12/17/2020 | SP | New Issue: RBC prices $2.88 million trigger autocallable contingent yield notes on Pfizer
|
12/15/2020 | SP | New Issue: UBS prices $237,000 trigger phoenix autocallables linked to Pfizer
|
12/15/2020 | SP | New Issue: CIBC sells $500,000 6% autocallable fixed-interest barrier notes on Pfizer
|
12/13/2020 | SP | New Issue: UBS sells $250,000 trigger return optimization securities on Pfizer
|
12/11/2020 | SP | New Issue: TD Bank prices $1.56 million contingent interest barrier autocalls with memory interest on Pfizer
|
12/10/2020 | SP | New Issue: UBS prices $100,000 return optimization securities linked to Pfizer
|
12/10/2020 | SP | New Issue: Morgan Stanley prices $1.55 million contingent income autocallables on stocks
|
12/8/2020 | SP | New Issue: UBS prices $100,000 return optimization securities linked to Pfizer
|
12/8/2020 | SP | New Issue: UBS prices $165,000 trigger phoenix autocallables linked to Pfizer
|
12/3/2020 | SP | New Issue: UBS prices $180,000 trigger phoenix autocallables linked to Pfizer
|
11/23/2020 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallables linked to Pfizer
|
11/22/2020 | SP | New Issue: UBS sells $6.65 million trigger autocallable contingent yield notes on basket of stocks
|
11/18/2020 | IGLM | Pfizer to fully redeem 5.8% notes due 2023, 1.95% notes due 2021
|
11/16/2020 | BKGNIG | S&P lowers Pfizer
|
11/16/2020 | BKGNIG | Moody’s downgrades Pfizer
|
11/14/2020 | SP | New Issue: Morgan Stanley sells $2.03 million contingent income autocallable notes on Pfizer
|
10/31/2020 | SP | New Issue: Morgan Stanley sells $4.42 million trigger autocallable contingent yield notes on Pfizer
|
10/26/2020 | SP | New Issue: Credit Suisse sells $2.83 million contingent coupon autocallable yield notes on stocks
|
10/14/2020 | SP | New Issue: UBS prices $155,000 trigger phoenix autocallables linked to Pfizer
|
10/14/2020 | SPSW | Agents sell $237 million to start Q3; single-index pricing improving; leverage still declining
|
10/13/2020 | SP | New Issue: UBS prices $182,000 trigger phoenix autocallables linked to Pfizer
|
10/12/2020 | SP | New Issue: UBS prices $158,000 trigger phoenix autocallables linked to Pfizer
|
9/23/2020 | SP | New Issue: UBS prices $2.08 million trigger autocallable contingent yield notes on Pfizer
|
8/26/2020 | SP | New Issue: UBS prices $203,000 trigger phoenix autocallables linked to Pfizer
|
8/21/2020 | SP | New Issue: Morgan Stanley sells $1.78 million contingent income autocalls on three stocks
|
8/20/2020 | SP | New Issue: HSBC prices $2.5 million contingent income barrier autocallables tied to three stocks
|
8/20/2020 | SP | New Issue: Credit Suisse sells $4.38 million contingent income autocalls on three stocks
|
8/18/2020 | SP | New Issue: Citigroup prices $850,000 contingent coupon autocallables on bank stocks
|
8/17/2020 | SP | New Issue: Citigroup prices $1.01 million contingent coupon autocallables on three stocks
|
8/13/2020 | SP | Credit Suisse plans contingent income autocalls on three stocks
|
7/8/2020 | SP | New Issue: RBC prices $1.36 million contingent coupon barrier autocalls on Pfizer
|
7/7/2020 | SP | New Issue: JPMorgan prices $1.28 million contingent coupon callable yield notes on Pfizer
|
6/23/2020 | SP | New Issue: JPMorgan sells $3.68 million trigger autocallable contingent yield notes on Pfizer
|
6/17/2020 | BK | Upjohn gets revolver, term loan as Mylan combination moves forward
|
6/15/2020 | BKIG | S&P rates Upjohn notes BBB-
|
6/15/2020 | IG | Upjohn expected to price about $12 billion of high-grade bonds to fund Mylan merger
|
6/3/2020 | SP | New Issue: Citigroup sells $1 million equity-linked notes on Pfizer, Johnson & Johnson
|
5/27/2020 | SP | New Issue: Morgan Stanley sells $10 million review notes tied to three stocks
|
5/22/2020 | IGLM | Pfizer, Wyeth recommend rejecting tender offer made by Huguenot
|
5/21/2020 | BKGNIG | Fitch rates Pfizer notes A
|
5/19/2020 | IG | New Issue: Pfizer details $4 billion of fixed-rate senior notes in four parts
|
5/18/2020 | EMHYPFPV | Market Commentary: Pfizer, Equinor, Alcon, RELX, Unum energy issuers tap primary
|
5/18/2020 | IG | Market Commentary: Pfizer, Equinor, energy issuers tap primary; SSA supply on deck; credit spreads tighten
|
5/18/2020 | IG | New Issue: Pfizer prices $4 billion of fixed-rate senior notes in four tranches
|
5/18/2020 | BKGNIG | Moody's gives Pfizer notes A1
|
5/18/2020 | IG | Market Commentary: Morning Commentary: Pfizer, energy suppliers, ICE, RELX, Unum to tap high-grade primary
|
5/18/2020 | BKGNIG | S&P rates Pfizer notes AA-
|
5/18/2020 | IG | Pfizer to conduct offering of fixed-rate notes in four tranches
|
5/8/2020 | SP | New Issue: GS Finance prices $4.05 million capped trigger securities on basket of 20 stocks
|
4/22/2020 | SP | New Issue: Citigroup prices $500,000 barrier securities linked to two stocks
|
4/2/2020 | SP | New Issue: Citigroup prices $500,000 barrier securities on linked to three stocks
|
3/31/2020 | SP | New Issue: UBS sells $548,540 contingent income autocallable notes on Pfizer
|
3/30/2020 | GNIG | Fitch rates Pfizer notes A
|
3/26/2020 | SP | New Issue: Credit Suisse $1.62 million contingent coupon autocallable yield notes on four stocks
|
3/25/2020 | EMHYPFPV | Market Commentary: High-grade supply heavy; NIKE, McDonald’s, HSBC, Deere, 3M, Pfizer price
|
3/25/2020 | IG | Market Commentary: High-grade supply heavy; NIKE, McDonald’s, HSBC, Deere, 3M, Pfizer price; credit spreads firm
|
3/25/2020 | IG | S&P lowers Cabot ratings
|
3/25/2020 | IG | S&P lowers Cabot ratings
|
3/25/2020 | GN | Fitch lowers Ellaktor
|
3/25/2020 | GN | Fitch lowers Ellaktor
|
3/25/2020 | GNIG | New Issue: Pfizer sells $1.25 billion 2.625% 10-year notes at Treasuries plus 185 bps spread
|
3/25/2020 | BKGNIG | Moody's assigns Pfizer notes A1
|
3/25/2020 | IG | Market Commentary: Morning Commentary: Heavy high-grade supply on tap; NIKE, 3M, McDonald’s to price notes
|
3/25/2020 | BKGNIG | S&P rates Pfizer notes AA-
|
3/25/2020 | GNIG | Pfizer offers 10-year notes to fund eligible social impact projects
|
3/19/2020 | SP | New Issue: Credit Suisse sells $2 million 8% autocallable reverse convertibles on pharma stocks
|
3/13/2020 | SP | New Issue: Citigroup sells $330,000 autocallable equity-linked notes on Anthem, Magna, Pfizer
|
3/13/2020 | SP | New Issue: Credit Suisse sells $751,000 buffered return equity securities on stock basket
|
3/13/2020 | SP | Credit Suisse to price contingent coupon autocallable yield notes on four stocks
|
3/2/2020 | SP | New Issue: Credit Suisse prices $4.3 million trigger autocallable contingent yield notes on Pfizer
|
2/25/2020 | SP | New Issue: JPMorgan prices $2.91 million capped return enhanced notes on stock basket
|
2/20/2020 | SP | New Issue: Morgan Stanley sells $800,000 contingent income autocalls on four stocks
|
1/28/2020 | SP | JPMorgan to price capped buffered return enhanced notes on stock basket
|
1/22/2020 | SP | New Issue: Credit Suisse $4.68 million contingent coupon autocallable yield notes on pharma stocks
|
1/7/2020 | SP | New Issue: JPMorgan sells $1.17 million contingent interest autocalls on pharma stocks
|
12/30/2019 | SP | New Issue: Credit Suisse sells $1.25 million contingent coupon autocallable reverse convertibles on three stocks
|
12/9/2019 | SP | New Issue: JPMorgan prices $1.2 million contingent interest autocalls on two stocks
|
12/4/2019 | SP | New Issue: UBS prices $150,000 trigger phoenix autocallables linked to Pfizer
|
11/27/2019 | SP | New Issue: JPMorgan prices $2 million contingent interest autocalls on two stocks
|
11/14/2019 | SP | JPMorgan to price contingent interest autocalls on two stocks
|
11/7/2019 | SP | New Issue: Morgan Stanley sells $1.19 million contingent income autocalls on stocks
|
9/30/2019 | SP | New Issue: HSBC prices $9.02 million trigger autocallables linked to Pfizer
|
9/20/2019 | SP | New Issue: RBC sells $7.19 million contingent coupon barrier autocalls on three stocks
|
9/16/2019 | SP | RBC to price contingent coupon barrier autocalls tied to three stocks
|
9/5/2019 | SP | New Issue: Citigroup prices $3.45 million contingent coupon autocallable notes on four stocks
|
8/13/2019 | SP | New Issue: UBS sells $524,000 trigger autocallable contingent yield notes on Pfizer
|
8/8/2019 | SP | New Issue: Credit Suisse prices $270,000 contingent coupon reverse convertibles linked to stocks
|
8/1/2019 | IG | Fitch lowers Pfizer
|
8/1/2019 | SP | UBS plans trigger autocallable contingent yield notes linked to Pfizer
|
7/29/2019 | IG | Moody’s reviews Pfizer for downgrade
|
7/29/2019 | IG | S&P lowers Pfizer rating
|
6/27/2019 | SP | New Issue: RBC sells $3.22 million contingent coupon barrier autocalls on three stocks
|
6/17/2019 | IG | S&P puts Pfizer on watch
|
6/17/2019 | BKBWIG | Pfizer to use mostly debt, some cash to buy Array for $11.4 billion
|
6/11/2019 | SP | New Issue: Barclays prices $1.59 million contingent income autocallables linked to Pfizer
|
5/31/2019 | SP | Barclays plans contingent income autocallables linked to Pfizer
|
5/21/2019 | SP | New Issue: Barclays prices $510,000 notes linked to pharmaceutical stocks
|
3/26/2019 | SP | New Issue: UBS sells $2.7 million trigger autocallable contingent yield notes on Pfizer
|
3/21/2019 | SP | UBS plans trigger autocallable contingent yield notes on Pfizer
|
3/8/2019 | EMHYPFPV | Market Commentary: Steady high-grade volume eyed; SoCal Edison holds calls; new issues mixed; CVS widens
|
3/8/2019 | IG | Market Commentary: Steady high-grade volume eyed; SoCal Edison holds calls; new issues mixed; CVS widens
|
3/8/2019 | IG | Market Commentary: Morning Commentary: SoCal Edison eyes market; Pfizer, Merck bonds mixed; inflows decline
|
3/6/2019 | SP | New Issue: Credit Suisse prices $5.54 million buffered PLUS tied to basket of 10 stocks
|
3/5/2019 | EMHYPFPV | Market Commentary: Merck, Lloyds, Lazard, Japan Finance price $7.5 billion of bonds; Dell, Cimarex eye market
|
3/5/2019 | IG | Market Commentary: Merck, Lloyds, Lazard, Japan Finance price $7.5 billion of bonds; Dell, Cimarex eye market
|
3/5/2019 | BKIGLM | Pfizer to refinance, redeem or buy back debt via $5 billion issue
|
3/5/2019 | IG | Market Commentary: Morning Commentary: Merck, Lazard, Lloyds, Japan Finance on tap; Dell, Cimarex eye market
|
3/5/2019 | IG | New Issue: Pfizer gives details on $5 billion of senior notes in five tranches
|
3/4/2019 | IG | Market Commentary: Investment-grade supply heavy; Pfizer, John Deere, MUFG, TD Bank, utilities among issuers
|
3/4/2019 | EMHYPFPV | Market Commentary: Investment-grade supply heavy; Pfizer, John Deere, MUFG, TD Bank, utilities among issuers
|
3/4/2019 | IG | New Issue: Pfizer prices $5 billion of senior notes in five tranches on tight side of talk
|
3/4/2019 | IG | Moody's rates Pfizer notes A1
|
3/4/2019 | IG | S&P rates Pfizer notes AA
|
3/4/2019 | IG | Market Commentary: Morning Commentary: Heavy supply from Pfizer, Leggett & Platt, Brown & Brown on tap
|
3/4/2019 | IG | Pfizer plans to conduct offering of fixed-rate notes in five parts
|
2/15/2019 | SP | BMO Harris plans annual digital yield generator CDs on stock basket
|
2/11/2019 | SP | Credit Suisse to price buffered PLUS tied to basket of 10 stocks
|
2/6/2019 | SP | New Issue: RBC sells $270,000 contingent coupon barrier autocallables on two pharma stocks
|
1/22/2019 | SP | RBC plans contingent coupon barrier autocallables tied to pharma stocks
|
12/7/2018 | EULM | Pfizer to redeem €1.14 billion of 5.75% notes due 2021 on Jan. 9
|
12/5/2018 | SP | New Issue: JPMorgan prices $1.61 million trigger autocallable contingent yield notes on Pfizer
|
12/5/2018 | SP | HSBC plans Income Plus CDs due 2021 on stocks with 5% potential coupon
|
12/5/2018 | SP | HSBC eyes Income Plus CDs due 2023 on stocks with 8% potential coupon
|
12/5/2018 | SP | HSBC eyes Income Plus CDs due 2023 on stocks with 5% potential coupon
|
12/5/2018 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
12/5/2018 | SP | Goldman Sachs plans variable coupon CDs due 2025 linked to 10 stocks
|
12/5/2018 | SP | JPMorgan to price digital contingent coupon CDs linked to 10 stocks
|
11/27/2018 | SP | New Issue: CIBC prices $1.19 million contingent coupon autocalls on stocks
|
11/21/2018 | SP | HSBC eyes Income Plus CDs due 2021 on stocks with 5% potential coupon
|
11/21/2018 | SP | HSBC plans Income Plus CDs tied to stocks with 9% potential coupon
|
11/21/2018 | SP | HSBC plans Income Plus CDs tied to stocks with 5% potential coupon
|
11/21/2018 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
11/21/2018 | SP | Goldman Sachs plans variable coupon CDs due 2025 linked to 10 stocks
|
10/23/2018 | SP | HSBC plans Income Plus CDs due 2023 on stocks with 8% potential coupon
|
10/23/2018 | SP | HSBC plans Income Plus CDs due 2023 on stocks with 5% potential coupon
|
10/23/2018 | SP | HSBC plans Income Plus CDs due 2021 on stocks with 5% potential coupon
|
10/23/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2025 on 10 stocks
|
10/23/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2023 on 10 stocks
|
9/20/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2025 on 10 stocks
|
9/20/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2023 on 10 stocks
|
9/7/2018 | EMHYPFPV | Market Commentary: Carlyle prices; primary busiest since 2016; Cigna, Pfizer notes mixed; Nordea, Eni firm
|
9/7/2018 | IG | Market Commentary: Carlyle prices; primary busiest since 2016; Cigna, Pfizer notes mixed; Nordea, Eni firm
|
9/7/2018 | IG | Market Commentary: Morning Commentary: High-grade market ends busiest week since 2016; outflows reported
|
9/6/2018 | EMHYPFPV | Market Commentary: Cigna prices $20 billion; CIBC sells notes; Carlyle, Mitsubishi UFJ eye deals
|
9/6/2018 | IG | Market Commentary: Cigna prices $20 billion; CIBC sells notes; Carlyle, Mitsubishi UFJ eye deals; Pfizer mixed
|
9/6/2018 | IG | Market Commentary: Cigna prices $20 billion; CIBC sells notes; Carlyle, Mitsubishi UFJ eye deals; Pfizer mixed
|
9/6/2018 | IG | Market Commentary: Morning Commentary: CIBC offers notes; Cigna deal looms; Carlyle markets offering
|
9/5/2018 | IG | Fitch lifts CenterPoint Energy
|
9/5/2018 | IG | Fitch rates Pfizer notes A+
|
9/5/2018 | IG | Market Commentary: Morning Commentary: Mizuho, General Motors, EIB offer notes; Cigna, Carlyle eye deals
|
9/5/2018 | IG | New Issue: Pfizer gives details on $5 billion issue of senior notes in six parts
|
9/4/2018 | EMHYPFPV | Market Commentary: High-grade volume strong; Pfizer, MUFG, Unilever, Caterpillar, Bunge, Duke price notes
|
9/4/2018 | IG | Market Commentary: High-grade volume strong; Pfizer, MUFG, Unilever, Caterpillar, Bunge, Duke price notes
|
9/4/2018 | IG | New Issue: Pfizer prices $5 billion of senior notes in six tranches
|
9/4/2018 | IG | S&P gives AA to Pfizer notes
|
9/4/2018 | IG | Moody’s rates Pfizer notes A1
|
9/4/2018 | IG | Market Commentary: Morning Commentary: Pfizer, MUFG, Caterpillar, Duke Realty, Bunge on tap in primary
|
9/4/2018 | IG | Pfizer intends to sell fixed- and floating-rate notes in six parts
|
8/23/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2025 on 10 stocks
|
8/23/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2023 on 10 stocks
|
7/23/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2025 on 10 stocks
|
7/23/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2023 on 10 stocks
|
7/2/2018 | SP | Market Commentary: HSBC’s 10% autocall on pharma stocks: not a buy-and-hold, low-risk strategy, advisers say
|
6/29/2018 | SP | HSBC to price 10% autocallable yield notes on pharmaceutical stocks
|
6/13/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2025 on 10 stocks
|
6/13/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2023 on 10 stocks
|
5/29/2018 | SP | New Issue: UBS sells $2.05 million 7% contingent yield trigger autocalls on Pfizer
|
5/14/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2025 on 10 stocks
|
5/14/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2023 on 10 stocks
|
4/23/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2023 on 10 stocks
|
4/23/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2025 on 10 stocks
|
3/19/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2023 on 10 stocks
|
3/19/2018 | SP | Goldman Sachs to price variable-coupon CDs due 2025 on 10 stocks
|
3/5/2018 | SP | New Issue: RBC sells $2.13 million 8% contingent yield trigger autocalls on Pfizer
|
2/20/2018 | SP | New Issue: Credit Suisse sells $95,023 call warrants linked to 20 stocks
|
2/16/2018 | SP | New Issue: Credit Suisse sells $149,992 call warrants linked to 20 stocks
|
2/16/2018 | SP | New Issue: Credit Suisse sells $83,500 call warrants linked to 20 stocks
|
2/15/2018 | SP | New Issue: Credit Suisse sells $149,951 call warrants linked to 20 stocks
|
2/15/2018 | SP | New Issue: Credit Suisse sells $175,000 return notes on basket of 20 stocks
|
2/8/2018 | SP | Credit Suisse to price 54-week call warrants linked to 20 stocks
|
2/8/2018 | SP | HSBC plans five-year Rate Builder CDs linked to Safety Rank 1 stocks
|
2/8/2018 | SP | Credit Suisse to price return notes linked to basket of 20 stocks
|
2/5/2018 | SP | New Issue: JPMorgan sells $5.81 million return notes linked to basket of 20 stocks
|
2/5/2018 | SP | New Issue: Credit Suisse prices $425,971 call warrants linked to 20 stocks
|
1/31/2018 | SP | Credit Suisse to price return notes linked to basket of 20 stocks
|
1/24/2018 | SP | JPMorgan to price return notes linked to basket of 20 stocks
|
1/24/2018 | SP | Credit Suisse to price 54-week call warrants linked to 20 stocks
|
1/24/2018 | SP | New Issue: Credit Suisse prices $639,916 call warrants linked to 20 stocks
|
1/23/2018 | SP | New Issue: Credit Suisse prices $2.79 million return notes on basket of 20 stocks
|
1/23/2018 | SP | New Issue: BMO prices $585,000 of one-year notes tied to basket of five stocks
|
1/18/2018 | SP | Credit Suisse to price return notes linked to basket of 20 stocks
|
1/17/2018 | SP | New Issue: Barclays prices $1.55 million phoenix autocallables on JPMorgan, Pfizer
|
1/12/2018 | SP | New Issue: CIBC prices $1.09 million contingent coupon autocallables tied to five stocks
|
1/8/2018 | EULM | Pfizer gets tenders for €24.7 million more 5.75% notes, lacks consents
|
12/21/2017 | EULM | Pfizer prices 5.75% note tender, gives response, waives consent test
|
12/15/2017 | EULM | Pfizer to issue £1.38 billion 2.735% notes in exchange, takes in tenders for £196.55 million
|
12/14/2017 | IGLM | Pfizer to issue 2.735% notes due 2043 in exchange; cash offer prices
|
12/8/2017 | IG | Fitch applies A+ to Pfizer notes
|
12/7/2017 | IG | S&P assigns AA to Pfizer notes
|
12/7/2017 | IG | Moody’s assigns A1 to Pfizer notes
|
12/7/2017 | IGLM | Pfizer holds exchange, cash offers for 6.5% notes due 2038, tender for 5.75% notes due 2021
|
12/4/2017 | SP | Market Commentary: RBC’s $1.37 million gears tied to basket of 29 stocks aim to reweight the Dow Jones Industrial
|
11/30/2017 | SP | New Issue: RBC sells $1.37 million buffer gears tied to basket of 29 stocks
|
11/14/2017 | SP | New Issue: Credit Suisse prices $2.59 million 8% autocallable reverse convertibles on four pharma stocks
|
11/13/2017 | SP | Bank of the West plans income advantage CDs linked to five stocks
|
11/1/2017 | SP | New Issue: HSBC sells $70,000 income plus notes tied to five stocks
|
10/19/2017 | SP | Goldman Sachs plans variable-coupon CDs due 2024 tied to 10 stocks
|
10/19/2017 | SP | Goldman Sachs to price variable-coupon CDs due 2022 on 10 stocks
|
10/19/2017 | SP | Goldman Sachs to price variable-coupon CDs due 2024 on 10 stocks
|
10/19/2017 | SP | New Issue: RBC sells $400,000 six-year individually capped notes tied to 15 stocks
|
9/18/2017 | SP | Goldman Sachs to price variable-coupon CDs due 2022 on 10 stocks
|
9/18/2017 | SP | Goldman Sachs plans variable-coupon CDs due 2024 tied to 10 stocks
|
9/18/2017 | SP | Goldman Sachs to price variable-coupon CDs due 2024 on 10 stocks
|
9/18/2017 | SP | JPMorgan to price digital contingent coupon CDs linked to 10 stocks
|
9/14/2017 | SP | New Issue: JPMorgan prices $1.45 million contingent buffer return enhanced notes tied to stocks
|
9/11/2017 | SP | HSBC to price autocallable target income CDs linked to five stocks
|
9/11/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 9% potential coupon
|
9/11/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 7.5% potential coupon
|
9/11/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 6% potential coupon
|
9/11/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 4.5% potential coupon
|
9/11/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 6.75% potential coupon
|
9/11/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 5.5% potential coupon
|
9/11/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 4.25% potential coupon
|
9/11/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 3% potential coupon
|
8/18/2017 | SP | Goldman Sachs to price seven-year variable-coupon CDs on 10 stocks
|
8/18/2017 | SP | Goldman Sachs to price variable-coupon CDs due 2024 on 10 stocks
|
8/18/2017 | SP | Goldman Sachs to price variable-coupon CDs due 2022 on 10 stocks
|
8/14/2017 | SP | HSBC to price autocallable target income CDs linked to five stocks
|
8/14/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 10% potential coupon
|
8/14/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 8.5% potential coupon
|
8/14/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 7% potential coupon
|
8/14/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 5.5% potential coupon
|
8/14/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 8% potential coupon
|
8/14/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 6.5% potential coupon
|
8/14/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 5% potential coupon
|
8/14/2017 | SP | HSBC plans Income Plus CDs linked to stocks with 3.5% potential coupon
|
7/18/2017 | IG | Fitch revises Pfizer to negative
|
7/10/2017 | SP | HSBC to price autocallable target income CDs linked to five stocks
|
7/10/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 3.25% potential coupon
|
7/10/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 9.5% potential coupon
|
7/10/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 8% potential coupon
|
7/10/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 6.5% potential coupon
|
7/10/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 5% potential coupon
|
7/10/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 7.5% potential coupon
|
7/10/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 6% potential coupon
|
7/10/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 4.5% potential coupon
|
7/7/2017 | SP | New Issue: HSBC sells $2.14 million autocallable contingent income barrier notes on stocks
|
6/29/2017 | SP | New Issue: Morgan Stanley prices $1.83 million contingent income autocallables on four stocks
|
6/19/2017 | SP | Morgan Stanley plans contingent income autocallables linked to stocks
|
5/4/2017 | SP | Bank of the West plans contingent variable-income CDs on 10 stocks
|
4/21/2017 | SP | Goldman Sachs to sell variable-coupon CDs due 2024 linked to 10 stocks
|
4/21/2017 | SP | Goldman Sachs plans variable-coupon CDs due 2024 tied to 10 stocks
|
4/21/2017 | SP | Goldman Sachs to price variable-coupon CDs due 2024 on 10 stocks
|
4/21/2017 | SP | Goldman Sachs to price variable-coupon CDs due 2022 on 10 stocks
|
4/19/2017 | SP | Bank of the West to sell contingent variable-income CDs on 10 stocks
|
4/18/2017 | SP | New Issue: UBS prices $451,000 trigger phoenix autocallables linked to Pfizer
|
4/18/2017 | SP | New Issue: UBS prices $295,000 trigger phoenix autocallables linked to Pfizer
|
4/18/2017 | SP | New Issue: UBS prices $353,000 trigger phoenix autocallables linked to Pfizer
|
4/18/2017 | SP | New Issue: UBS prices $232,000 trigger phoenix autocallables linked to Pfizer
|
4/18/2017 | SP | New Issue: UBS prices $224,000 trigger phoenix autocallables linked to Pfizer
|
4/17/2017 | SP | New Issue: CIBC prices $2.75 million contingent coupon autocallables linked to three stocks
|
3/31/2017 | SP | New Issue: HSBC prices $1.07 million seven-year income plus notes linked to five stocks
|
3/31/2017 | SP | New Issue: HSBC prices $772,000 seven-year income plus notes linked to five stocks
|
3/27/2017 | SP | HSBC plans income plus notes on five stocks with 8.25% potential coupon
|
3/27/2017 | SP | HSBC plans income plus notes on five stocks with 3.5% potential coupon
|
3/23/2017 | SP | TD Bank amends Cusip for Raymond James Quality Yield Equity notes
|
3/20/2017 | SP | TD Bank plans notes linked to 23 Raymond James Quality Yield stocks
|
3/6/2017 | SP | Goldman Sachs plans to price variable-coupon CDs due 2024 on 10 stocks
|
3/6/2017 | SP | Goldman Sachs Bank to price variable-coupon CDs due 2024 on 10 stocks
|
3/6/2017 | SP | Goldman Sachs Bank to price variable-coupon CDs due 2022 on 10 stocks
|
3/2/2017 | SP | New Issue: HSBC prices $992,000 seven-year income plus notes linked to five stocks
|
3/1/2017 | IG | Fitch rates Pfizer notes A+
|
2/28/2017 | IG | S&P rates Pfizer notes AA
|
2/28/2017 | IG | Moody’s applies A1 to Pfizer notes
|
2/24/2017 | EMHYPFPV | Market Commentary: Fannie Mae, Pfizer sell notes; Bristol-Myers steady; Mizuho, Parker-Hannifin tighten
|
2/24/2017 | IG | Market Commentary: Fannie Mae, Pfizer sell notes; Bristol-Myers steady; Mizuho, Parker-Hannifin tighten
|
2/24/2017 | IG | New Issue: Pfizer prices $1.07 billion 30-year Taipei Exchange-listed notes at par to yield 4.2%
|
2/24/2017 | IG | Fitch rates Pfizer notes A+
|
2/24/2017 | SP | New Issue: UBS sells $3.6 million trigger autocallable contingent yield notes on Pfizer
|
2/24/2017 | IG | S&P rates Pfizer notes AA
|
2/24/2017 | IG | Moody’s applies A1 to Pfizer notes
|
2/24/2017 | IG | Market Commentary: Morning Commentary: Pfizer markets 30-year notes; Bristol-Myers improves in secondary market
|
2/24/2017 | IG | Pfizer to price 30-year Taipei Exchange-listed notes via bookrunners BNP and Deutsche Bank
|
2/22/2017 | SP | HSBC plans income plus notes tied to five stocks with 1%-9% coupon
|
2/16/2017 | SP | UBS eyes trigger autocallable contingent yield notes linked to Pfizer
|
2/13/2017 | SP | Goldman Sachs plans variable-coupon CDs due 2022 linked to 10 stocks
|
2/13/2017 | SP | Goldman Sachs plans variable-coupon CDs due 2024 linked to 10 stocks
|
2/13/2017 | SP | Goldman Sachs to price variable-coupon CDs due 2024 tied to 10 stocks
|
1/31/2017 | SP | New Issue: HSBC prices $1.43 million seven-year income plus notes linked to five stocks
|
1/10/2017 | SP | New Issue: UBS prices $243,000 trigger phoenix autocallables linked to Pfizer
|
1/10/2017 | SP | New Issue: UBS prices $376,000 trigger phoenix autocallables linked to Pfizer
|
1/10/2017 | SP | New Issue: UBS prices $371,000 trigger phoenix autocallables linked to Pfizer
|
1/10/2017 | SP | New Issue: UBS prices $285,000 trigger phoenix autocallables linked to Pfizer
|
1/10/2017 | SP | Goldman Sachs plans variable-coupon CDs due 2027 linked to 10 stocks
|
1/10/2017 | SP | Goldman Sachs plans variable-coupon CDs due 2024 tied to 10 stocks
|
1/10/2017 | SP | Bank of the West plans income advantage CDs on five-stock basket
|
1/10/2017 | SP | Bank of the West plans income advantage CDs linked to five stocks
|
1/10/2017 | SP | Goldman Sachs plans variable-coupon CDs due 2024 linked to 10 stocks
|
1/10/2017 | SP | Bank of the West to sell contingent variable-income CDs on 10 stocks
|
1/10/2017 | SP | Goldman Sachs plans variable-coupon CDs due 2022 linked to 10 stocks
|
1/4/2017 | SP | New Issue: BMO prices $528,000 of notes linked to basket of stocks
|
12/30/2016 | SP | New Issue: JPMorgan prices $6 million contingent interest autocallables tied to three stocks
|
12/22/2016 | EMHYPFPV | Market Commentary: BB&T prices $850 million floaters; bonds mixed; Anheuser-Busch firms; Duke Energy eases
|
12/22/2016 | IG | Market Commentary: BB&T prices $850 million floaters; bonds mixed; Anheuser-Busch firms; Duke Energy eases
|
12/22/2016 | IG | Market Commentary: Morning Commentary: BB&T to sell notes; Pfizer stronger; secondary market volume thins
|
12/20/2016 | SP | HSBC eyes income plus note on five stocks with 9.25% potential coupon
|
12/19/2016 | SP | Goldman Sachs plans variable-coupon CDs due 2026 linked to 10 stocks
|
12/19/2016 | SP | Goldman Sachs to price variable-coupon CDs due 2023 tied to 10 stocks
|
12/19/2016 | SP | Goldman Sachs plans variable-coupon CDs due 2023 linked to 10 stocks
|
12/19/2016 | SP | Goldman Sachs plans variable-coupon CDs due 2021 linked to 10 stocks
|
12/16/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 8.75% potential coupon
|
12/16/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 7.5% potential coupon
|
12/16/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 6.25% potential coupon
|
12/16/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 5% potential coupon
|
12/16/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 7% potential coupon
|
12/16/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 5.75% potential coupon
|
12/16/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 4.5% potential coupon
|
12/9/2016 | SP | BMO plans notes tied to Cisco, Coke, Pfizer, Procter & Gamble, Verizon
|
11/22/2016 | SP | New Issue: Morgan Stanley prices $6.24 million trigger participation notes linked to 45 stocks
|
11/21/2016 | SP | New Issue: Bank of America prices $2.5 million autocallable yield notes tied to three stocks
|
11/21/2016 | IGLM | Pfizer holders tender $1.94 billion of 6.2% notes due 2019 in offer
|
11/18/2016 | EMHYPFPV | Market Commentary: Light volume seen for holiday week; Abbott, Pfizer mixed; Chevron Phillips Chemical firms
|
11/18/2016 | IG | Market Commentary: Light volume forecast for holiday week; Abbott, Pfizer mixed; Chevron Phillips Chemical firms
|
11/18/2016 | IGLM | Pfizer prices tender offer for $3.25 billion of 6.2% notes due 2019
|
11/15/2016 | IG | Fitch rates Pfizer notes A+
|
11/15/2016 | IG | New Issue: Pfizer gives details on $6 billion five-part sale of fixed-rate notes
|
11/14/2016 | EMHYPFPV | Market Commentary: Pfizer, Morgan Stanley, Duke Energy Carolinas, American Water price; credit spreads ease
|
11/14/2016 | IG | Market Commentary: Pfizer, Morgan Stanley, Duke Energy Carolinas, American Water sell bonds; credit spreads ease
|
11/14/2016 | IG | New Issue: Pfizer prices $6 billion of fixed-rate notes in five tranches
|
11/14/2016 | IG | Moody’s applies A1 to Pfizer notes
|
11/14/2016 | IG | Market Commentary: Morning Commentary: Pfizer among issuers set to tap primary market; Consolidated Edison firms
|
11/14/2016 | IG | Pfizer plans to conduct offering of fixed-rate notes in five parts
|
11/14/2016 | IGLM | Pfizer begins tender for $3.25 billion of 6.2% senior notes due 2019
|
11/7/2016 | SP | Goldman Sachs to price variable-coupon CDs due 2023 on 10 stocks
|
11/7/2016 | SP | Goldman Sachs Bank plans variable-coupon CDs due 2023 on 10 stocks
|
11/7/2016 | SP | Goldman Sachs Bank plans variable-coupon CDs due 2026 on 10 stocks
|
11/7/2016 | SP | Goldman Sachs Bank plans variable-coupon CDs due 2021 on 10 stocks
|
11/7/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 4.25% potential coupon
|
11/7/2016 | SP | HSBC plans Income Plus CDs on five stocks with 3.25% potential coupon
|
11/7/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 2.25% potential coupon
|
11/7/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 5.75% potential coupon
|
11/7/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 4.5% potential coupon
|
11/7/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 3.25% potential coupon
|
11/7/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
11/7/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
10/10/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
10/10/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
10/10/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 5% potential coupon
|
10/10/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 3.75% potential coupon
|
10/10/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 2.5% potential coupon
|
10/10/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 4% potential coupon
|
10/10/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 3% potential coupon
|
10/10/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 2% potential coupon
|
10/7/2016 | SP | New Issue: RBC prices $6.47 million Accelerated Return Notes linked to pharma stocks
|
10/7/2016 | SP | Bank of the West to sell contingent variable-income CDs on 10 stocks
|
9/27/2016 | SP | New Issue: BMO prices $48.26 million notes linked to Raymond James quality yield stock basket
|
9/26/2016 | IG | Moody’s revises Pfizer to stable
|
9/26/2016 | SP | RBC plans 14-month Accelerated Return Notes linked to pharma stocks
|
9/13/2016 | SP | Barclays Bank Delaware plans to price seven-year CDs tied to 10 stocks
|
9/13/2016 | SP | Barclays Bank Delaware plans to price six-year CDs tied to 10 stocks
|
9/13/2016 | SP | Barclays Bank Delaware plans to price five-year CDs tied to 10 stocks
|
9/12/2016 | SP | Market Commentary: BMO’s notes linked to Raymond James quality yield stock basket offer access to popular sector
|
9/12/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
9/12/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
9/12/2016 | SP | Bank of the West plans income advantage CDs linked to five stocks
|
9/9/2016 | SP | BMO plans notes linked to Raymond James quality yield stock basket
|
8/23/2016 | SP | New Issue: JPMorgan prices $5.29 million contingent interest autocallables linked to four stocks
|
8/16/2016 | SP | New Issue: Barclays prices $1.09 million trigger autocallable contingent yield notes on Pfizer
|
8/9/2016 | SP | Barclays plans trigger autocallable contingent yield notes on Pfizer
|
8/9/2016 | SP | Bank of the West offers contingent variable-income CDs on 10 stocks
|
8/8/2016 | SP | New Issue: JPMorgan sells $980,000 autocallable contingent interest notes on three stocks
|
8/8/2016 | SP | Barclays Bank Delaware plans to price seven-year CDs tied to 10 stocks
|
8/8/2016 | SP | Barclays Bank Delaware plans to price six-year CDs tied to 10 stocks
|
8/8/2016 | SP | Barclays Bank Delaware plans to price five-year CDs tied to 10 stocks
|
8/8/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
8/8/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
8/3/2016 | SP | JPMorgan plans contingent interest autocallables tied to four stocks
|
7/28/2016 | SP | JPMorgan plans contingent interest autocallables tied to three stocks
|
7/11/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
7/11/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
7/11/2016 | SP | Barclays Bank Delaware plans to price seven-year CDs tied to 10 stocks
|
7/11/2016 | SP | Barclays Bank Delaware plans to price six-year CDs tied to 10 stocks
|
7/11/2016 | SP | Barclays Bank Delaware plans to price five-year CDs tied to 10 stocks
|
7/6/2016 | SP | Market Commentary: Bank of the West to price a pair of basket CDs aimed at different breeds of income-seekers
|
7/5/2016 | SP | Bank of the West aims to sell income advantage CDs tied to five stocks
|
7/5/2016 | SP | Bank of the West plans income advantage CDs tied to five-stock basket
|
6/24/2016 | CV | Pfizer closes Anacor acquisition, triggers convertibles’ make-whole
|
6/15/2016 | SP | New Issue: UBS prices $1.14 million trigger phoenix autocallables linked to Pfizer
|
6/13/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
6/13/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
6/13/2016 | SP | Barclays Bank Delaware plans to price seven-year CDs tied to 10 stocks
|
6/13/2016 | SP | Barclays Bank Delaware to price seven-year CDs linked to 10 stocks
|
6/13/2016 | SP | Barclays Bank Delaware to price six-year CDs linked to 10 stocks
|
6/13/2016 | SP | Barclays Bank Delaware to price five-year CDs linked to 10 stocks
|
6/6/2016 | SP | Bank of America’s $4.36 million leveraged notes tied to eight stocks offer mildly bullish bet
|
6/3/2016 | SP | New Issue: Bank of America prices $4.36 million Accelerated Return Notes linked to eight stocks
|
6/3/2016 | SP | Bank of the West to sell contingent variable-income CDs on 10 stocks
|
6/2/2016 | EMHYMUPFPV | Market Commentary: Aetna, Citigroup, Brixmor, Nasdaq, RBC tap bond market; Mylan tightens; Pfizer mixed
|
6/2/2016 | IG | Market Commentary: Aetna, Citigroup, Brixmor, Nasdaq, RBC tap bond market; Mylan tightens; Pfizer mixed
|
6/2/2016 | IG | Market Commentary: Morning Commentary: Mylan notes tighten; Pfizer paper mixed; Libor yield rises 2 bps
|
6/1/2016 | IG | Fitch rates Pfizer notes A+
|
6/1/2016 | IG | New Issue: Pfizer details sale of $5 billion notes in five tranches
|
5/31/2016 | EMHYMUPFPV | Market Commentary: Mylan, Pfizer, JPMorgan, Norfolk, Southern California Gas price; Anheuser Busch firms
|
5/31/2016 | IG | Market Commentary: Mylan, Pfizer, JPMorgan, Norfolk, Southern California Gas price; Anheuser Busch firms
|
5/31/2016 | IG | New Issue: Pfizer prices $5 billion of notes in five tranches
|
5/31/2016 | IG | S&P applies AA to Pfizer notes
|
5/31/2016 | IG | Moody’s provides A1 to Pfizer notes
|
5/31/2016 | IG | Market Commentary: Morning Commentary: Pfizer, Norfolk to price; Walgreens stronger; credit spreads open tighter
|
5/31/2016 | IG | Pfizer intends to sell 2018, 2019, 2021 and 2026 notes, reissue 4.4% notes due 2044
|
5/20/2016 | SP | Bank of America plans 14-month Accelerated Return Notes tied to stocks
|
5/17/2016 | SP | New Issue: JPMorgan prices $676,000 contingent interest autocallables linked to pharma stocks
|
5/16/2016 | IG | Moody’s changes Pfizer to negative
|
5/9/2016 | SP | Barclays Bank Delaware plans seven-year CDs linked to 10 stocks
|
5/9/2016 | SP | Barclays Bank Delaware to price seven-year CDs linked to 10 stocks
|
5/9/2016 | SP | Barclays Bank Delaware to price six-year CDs linked to 10 stocks
|
5/9/2016 | SP | Barclays Bank Delaware to price five-year CDs linked to 10 stocks
|
5/5/2016 | SP | JPMorgan plans autocallable contingent interest notes on three stocks
|
5/5/2016 | SP | Bank of the West to sell income advantage CDs linked to five stocks
|
5/5/2016 | SP | Bank of the West to sell income advantage CDs linked to five stocks
|
5/5/2016 | SP | Bank of the West plans contingent variable-income CDs on 10 stocks
|
4/26/2016 | SP | New Issue: UBS prices $3.47 million trigger autocallables linked to Pfizer
|
4/26/2016 | SP | New Issue: Bank of Montreal prices $27.5 million notes linked to Raymond James quality yield stock basket
|
4/20/2016 | SP | UBS plans trigger autocallable contingent yield notes linked to Pfizer
|
4/13/2016 | SP | Bank of Montreal plans notes on 24 Raymond James-picked stocks
|
4/11/2016 | SP | Barclays Bank Delaware will price seven-year CDs linked to 10 stocks
|
4/11/2016 | SP | Barclays Bank Delaware will price six-year CDs linked to 10 stocks
|
4/11/2016 | SP | Barclays Bank Delaware will price five-year CDs linked to 10 stocks
|
4/7/2016 | EMHYMUPFPV | Market Commentary: Standard Chartered prices tight; JPMorgan firms; Citi eases; Thermo tightens; Pfizer improves
|
4/7/2016 | IG | Market Commentary: Standard Chartered prices tight; JPMorgan firms; Citi eases; Thermo tightens; Pfizer improves
|
4/6/2016 | EMHYMUPFPV | Market Commentary: KfW, Banque Federative, Swedish Export bring deals; Pfizer widens; Newell Rubbermaid firms
|
4/6/2016 | IG | Market Commentary: KfW, Banque Federative, Swedish Export Credit do deals; Pfizer widens; Newell Rubbermaid firms
|
4/4/2016 | EMHYMUPFPV | Market Commentary: Primary sees $12 billion issuance from Target, BMW, others; Pfizer, AT&T tighten modestly
|
4/4/2016 | IG | Market Commentary: Primary sees $12 billion of issuance from Target, BMW, others; Pfizer, AT&T tighten modestly
|
4/4/2016 | SP | Bank of the West plans income advantage CDs tied to five-stock basket
|
4/4/2016 | SP | Bank of the West to sell income advantage CDs linked to five stocks
|
3/29/2016 | SP | New Issue: Deutsche Bank prices $715,000 phoenix autocallables on pharma stocks
|
3/8/2016 | SP | Barclays to price CDs linked to 10 stocks with 0.75% minimum coupon
|
3/8/2016 | SP | Barclays to price CDs linked to 10 stocks with 0.5% minimum coupon
|
3/8/2016 | SP | Barclays to price CDs linked to 10 stocks with 0.25% minimum coupon
|
3/3/2016 | SP | New Issue: HSBC prices $5.47 million 7% STEP Income Securities tied to four stocks
|
2/18/2016 | SP | New Issue: UBS prices $476,950 trigger phoenix autocallables linked to Pfizer
|
2/12/2016 | SP | HSBC plans one-year 7% STEP Income Securities tied to four stocks
|
2/11/2016 | SP | Morgan Stanley to price buffered return notes linked to 30 stocks
|
2/10/2016 | SP | UBS to price five-year trigger phoenix autocallables linked to Pfizer
|
2/8/2016 | SP | Barclays plans CDs linked to 10 common stocks with 1% minimum coupon
|
2/8/2016 | SP | Barclays plans CDs linked to 10 common stocks with 0.5% minimum coupon
|
2/2/2016 | SP | UBS plans return optimization notes due 2017 with cap tied to stocks
|
1/12/2016 | EMHYMUPFPV | Market Commentary: Financials storm investment-grade primary; MetLife notes flat; Pfizer, AstraZeneca firm
|
1/12/2016 | IG | Market Commentary: Financials storm investment-grade primary; MetLife notes flat; Pfizer, AstraZeneca firm
|
12/17/2015 | SP | New Issue: Nomura prices $595,000 9% autocallable notes due 2017 on three stocks
|
12/15/2015 | SP | New Issue: UBS prices $305,000 trigger phoenix autocallables linked to Pfizer
|
12/10/2015 | SP | New Issue: UBS prices $630,000 trigger phoenix autocallables linked to Pfizer
|
12/3/2015 | EMHYMUPFPV | Market Commentary: BofA prices after delay, downgrade; ECB disappoints markets; Dollar General, Pfizer firm
|
12/3/2015 | IG | Market Commentary: BofA prices after delay, downgrade; ECB disappoints markets; Dollar General, Pfizer firm
|
11/25/2015 | EMHYMUPFPV | Market Commentary: High-grade primary expected to be busy in December; Pfizer, Burlington Northern tighten
|
11/25/2015 | IG | Market Commentary: High-grade primary expected to be busy in December; Pfizer, Burlington Northern tighten
|
11/25/2015 | SP | Nomura plans notes on worst of McDonald’s, Pfizer, Wal-Mart stocks
|
11/24/2015 | IG | Fitch puts Pfizer on watch
|
11/24/2015 | IG | Market Commentary: Morning Commentary: Allergan tightens; Wells Fargo paper improves; credit spreads ease
|
11/23/2015 | EMHYMUPFPV | Market Commentary: Lloyds, HCP, MetLife do deals; Vodafone scraps 30-year bonds; Pfizer trades mostly flat
|
11/23/2015 | IG | Market Commentary: Lloyds, HCP, MetLife do deals; Vodafone scraps 30-year bonds; Pfizer trades mostly flat
|
11/23/2015 | IG | S&P: Pfizer on negative watch with Allergan deal
|
11/23/2015 | IG | Moody’s affirms Pfizer
|
11/11/2015 | SP | New Issue: UBS prices $3.43 million trigger phoenix autocallables linked to Pfizer
|
11/10/2015 | HYLM | Pharmaq exercises call on senior secured floating-rate bonds due 2019
|
11/10/2015 | IG | New Issue: Zoetis details $1.25 billion sale of notes in five-, 10-year tranches
|
11/9/2015 | IG | Market Commentary: Chevron, ANZ, Delphi among onslaught of issuers; energy bonds mixed; credit spreads widen
|
11/9/2015 | IG | New Issue: Zoetis sells $1.25 billion of senior notes in five-, 10-year tranches
|
11/9/2015 | IG | Zoetis planning to offer senior notes in two maturities
|
11/4/2015 | SP | UBS plans to price trigger phoenix autocallables linked to Pfizer
|
10/23/2015 | SP | New Issue: RBC prices $2.7 million bullish barrier enhanced notes on five stocks
|
10/20/2015 | SP | New Issue: RBC prices $410,000 bullish barrier enhanced notes linked to five stocks
|
10/19/2015 | SP | RBC plans 0% bullish barrier enhanced notes on basket of five stocks
|
10/15/2015 | SP | RBC plans bullish barrier enhanced return notes on five stocks
|
10/2/2015 | IGLM | Pfizer wraps exchange for four series of Hospira notes after buyout
|
9/18/2015 | IGLM | Pfizer gives early tender update in exchange offers for Hospira notes
|
9/11/2015 | SP | New Issue: JPMorgan prices $1 million contingent buffered notes tied to 11 stocks
|
9/10/2015 | SP | New Issue: Deutsche Bank prices $180,623 call warrants linked to 11 stocks
|
9/10/2015 | SP | New Issue: Deutsche Bank prices $5.96 million knock-out notes on stock basket
|
9/8/2015 | IG | Fitch assigns A+ to Pfizer notes
|
9/8/2015 | SP | New Issue: Deutsche Bank prices $1.29 million knock-out notes on stock basket
|
9/4/2015 | IG | S&P applies AA to Pfizer notes
|
9/4/2015 | IGLM | Pfizer begins exchange offers, consent solicitations for Hospira notes
|
9/2/2015 | SP | New Issue: UBS prices $2.19 million trigger phoenix autocallables linked to Pfizer
|
9/2/2015 | SP | New Issue: RBC prices $2 million 8% airbag autocallables linked to Pfizer
|
8/25/2015 | SP | UBS plans to price trigger phoenix autocallables linked to Pfizer
|
8/12/2015 | SP | Barclays Bank Delaware to price six-year CDs linked to five stocks
|
8/12/2015 | SP | Barclays Bank Delaware to price seven-year CDs tied to five stocks
|
8/12/2015 | SP | Barclays Bank Delaware to price five-year CDs linked to five stocks
|
8/4/2015 | SP | Bank of the West plans seven-year income CDs linked to Dividend Kings
|
7/14/2015 | SP | New Issue: Credit Suisse prices $1.85 million trigger phoenix autocallables tied to Pfizer
|
7/13/2015 | SP | Barclays Bank Delaware to price seven-year CDs linked to five stocks
|
7/13/2015 | SP | Barclays Bank Delaware to price six-year CDs linked to five stocks
|
7/13/2015 | SP | Barclays Bank Delaware to price five-year CDs linked to five stocks
|
7/13/2015 | SP | Barclays Bank Delaware to price three-year CDs linked to five stocks
|
7/7/2015 | SP | Credit Suisse to price trigger phoenix autocallables based on Pfizer
|
6/24/2015 | SP | New Issue: JPMorgan prices $2.17 million trigger phoenix autocallables on Pfizer
|
6/17/2015 | SP | JPMorgan plans to price trigger phoenix autocallables linked to Pfizer
|
6/2/2015 | SP | Bank of the West plans seven-year income CDs linked to 10 stocks
|
4/28/2015 | SP | New Issue: HSBC prices $1.14 million income plus notes due 2022 on five stocks
|
4/1/2015 | SP | HSBC plans income plus notes on stocks with 1% minimum coupon
|
2/5/2015 | EMHYMUPFPV | Market Commentary: Merck upsizes jumbo deal; Japan Finance, Costco price; Pfizer, Hospira active on acquisition
|
2/5/2015 | IG | Market Commentary: Merck upsizes jumbo deal; Japan Finance, Costco price; Pfizer, Hospira active on acquisition
|
2/5/2015 | BKIG | Pfizer plans debt financing for $17 billion acquisition of Hospira
|
2/5/2015 | IG | Moody’s affirms Pfizer
|
12/10/2014 | SP | New Issue: Deutsche prices $1.19 million trigger autocallables linked to Pfizer
|
12/4/2014 | SP | Deutsche Bank plans trigger autocallable securities tied to Pfizer
|
12/1/2014 | SP | New Issue: RBC prices $2.12 million buffered optimization notes tied to health care stocks
|
10/15/2014 | SP | New Issue: Credit Suisse prices $1.36 million return enhanced notes linked to Pfizer
|
10/8/2014 | SP | Credit Suisse to price return enhanced notes linked to Pfizer
|
10/2/2014 | SP | New Issue: Bank of America changes Cusip on contingent income autocallables on three stocks
|
9/30/2014 | SP | New Issue: Bank of America prices $2.5 million contingent income autocallables on three stocks
|
8/12/2014 | SP | New Issue: HSBC prices $2.82 million dual directional contingent buffered enhanced notes on Pfizer
|
8/6/2014 | SP | HSBC plans dual directional contingent buffered notes linked to Pfizer
|
8/5/2014 | SP | New Issue: HSBC prices $1.08 million dual directional contingent buffered enhanced notes on Pfizer
|
7/31/2014 | SP | HSBC plans dual directional contingent buffered enhanced notes on Pfizer
|
7/29/2014 | IG | Market Commentary: Morning Commentary: High-grade bond spreads steady; eBay firms; Pfizer mostly unchanged
|
7/23/2014 | SP | New Issue: UBS prices $3.86 million trigger phoenix autocallables linked to Pfizer
|
7/16/2014 | SP | UBS plans five-year trigger phoenix autocallable notes linked to Pfizer
|
7/9/2014 | SP | JPMorgan plans to price return notes linked to basket of 16 stocks
|
7/1/2014 | SP | New Issue: JPMorgan prices $2.27 million trigger autocallable optimization securities on Pfizer
|
6/25/2014 | SP | JPMorgan plans trigger autocallable notes linked to Pfizer
|
6/17/2014 | SP | New Issue: Deutsche Bank prices $3.8 million trigger phoenix autocallables linked to Pfizer
|
6/10/2014 | SP | New Issue: HSBC prices $500,000 uncapped trigger return notes linked to Pfizer
|
6/9/2014 | SP | Deutsche Bank plans trigger phoenix autocallables tied to Pfizer
|
6/5/2014 | SP | HSBC amends issue date for uncapped trigger return notes on Pfizer
|
6/4/2014 | SP | HSBC to price uncapped trigger return enhanced notes linked to Pfizer
|
5/14/2014 | IG | Fitch rates Pfizer notes A+
|
5/13/2014 | IG | New Issue: Pfizer details $4.5 billion sale of notes in five tranches
|
5/12/2014 | IG | Pfizer plans four-part offering of notes
|
5/12/2014 | IG | S&P rates Pfizer notes AA
|
5/12/2014 | IG | Moody's assigns Pfizer notes A1
|
5/12/2014 | IG | Market Commentary: Pfizer, Barclays among issuers to price about $13 billion of bonds; new paper mostly flat
|
5/12/2014 | IG | Market Commentary: Midday Commentary: Primary gears up for busy week; spreads tighter; Caterpillar Financial firms
|
5/12/2014 | IG | New Issue: Pfizer prices $4.5 billion of notes in five tranches due 2017-2044
|
5/9/2014 | IG | Market Commentary: Midday Commentary: Spreads softer; financials mixed; Morgan Stanley eases; Pfizer firms
|
4/30/2014 | SP | New Issue: Barclays prices $389,000 trigger phoenix autocallables linked to Pfizer
|
4/8/2014 | SP | Barclays plans trigger phoenix autocallable notes linked to Pfizer
|
11/14/2013 | IGLM | Pfizer subsidiary to redeem all $1.75 billion of 5.5% notes due 2014
|
9/26/2013 | SP | New Issue: HSBC prices $50,000 income plus notes tied to five stocks with 6% potential coupon
|
9/26/2013 | SP | New Issue: HSBC sells $1.96 million income plus notes on five stocks with 10% potential coupon
|
6/4/2013 | IG | Fitch rates Pfizer debt A+
|
5/29/2013 | IG | Market Commentary: Midday Commentary: Spreads in high-grade secondary market widen; new Pfizer notes weaker
|
5/29/2013 | IG | Market Commentary: Alexandria sells; GECC offers hybrid; secondary spreads widen during 'very volatile' session
|
5/28/2013 | IG | Market Commentary: Pfizer returns to market with $4 billion trade; Northrop, Agrium price; Pfizer notes firm
|
5/28/2013 | IG | New Issue: Pfizer taps market for $4 billion of notes in five tranches
|
5/28/2013 | IG | Pfizer eyes market for five-tranche note sale Tuesday
|
5/28/2013 | IG | Pfizer eyes market for multi-tranche note sale Tuesday
|
5/28/2013 | IG | S&P rates Pfizer notes AA
|
5/28/2013 | IG | Moody's rates Pfizer notes A1
|
11/5/2012 | IG | Market Commentary: AbbVie prices huge deal after delay; Boardwalk Pipelines, Invesco sell; secondary sees volume
|
8/28/2012 | IGLM | Pfizer lacks needed consents from holders of two Pharmacia note series
|
8/15/2012 | IGLM | Pfizer solicits consents to amend five series of Pharmacia debentures
|
8/13/2012 | IG | Pfizer to exchange some debt ahead of Zoetis initial public offering
|
6/26/2012 | SP | New Issue: HSBC prices $714,000 income plus notes tied to stocks with 1% minimum coupon
|
6/26/2012 | SP | New Issue: HSBC prices $76,000 income plus notes tied to stocks with 0.5% minimum coupon
|
6/8/2012 | SP | HSBC plans income plus notes tied to stocks with 0.5% minimum coupon
|
6/8/2012 | SP | HSBC plans income plus notes tied to stocks with 1.5% minimum coupon
|
5/30/2012 | IG | Market Commentary: Kraft does $6 billion monster deal, tightens in secondary; Charles Schwab sells preferreds
|
5/10/2012 | CVIGPF | Pfizer files automatic shelf registration for stock, preferreds, debt
|
4/24/2012 | SP | New Issue: UBS prices $2.4 million trigger phoenix autocallables linked to Pfizer
|
4/23/2012 | IG | Moody's: Pfizer sale is negative
|
4/23/2012 | IG | Fitch: Pfizer unaffected
|
4/17/2012 | SP | UBS to price trigger phoenix autocallables linked to Pfizer stock
|
1/12/2012 | SP | New Issue: Citi updates Cusip on $18 million 2.8% exchangeables linked to Pfizer
|
12/29/2011 | SP | RBC redeems $3.95 million trigger phoenix autocallables tied to Pfizer
|
11/28/2011 | IG | Moody's rates Pfizer loan A1
|
11/28/2011 | SP | New Issue: Deutsche prices $950,000 capped knock-out notes linked to Pfizer
|
11/22/2011 | SP | Deutsche Bank plans one-year capped knock-out notes linked to Pfizer
|
11/22/2011 | SP | New Issue: Bank of Montreal prices $2.3 million 11.53% reverse exchangeables linked to five stocks
|
11/22/2011 | SP | New Issue: JPMorgan prices $1.16 million capped knock-out notes linked to Pfizer
|
11/15/2011 | SP | JPMorgan plans single observation knock-out notes tied to Pfizer
|
10/3/2011 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Pfizer
|
9/23/2011 | IG | Fitch lowers Pfizer
|
9/20/2011 | SP | New Issue: RBC prices $8.86 million 8.63% trigger yield optimization notes linked to Pfizer
|
9/19/2011 | SP | New Issue: JPMorgan prices $3.98 million 8.25% upside autocallables on Pfizer
|
9/15/2011 | SP | RBC plans 7%-9.6% trigger yield optimization notes linked to Pfizer
|
9/13/2011 | SP | RBC plans 7%-9.6% trigger yield optimization notes linked to Pfizer
|
9/7/2011 | SP | New Issue: Credit Suisse prices $1.92 million capped knock-out notes on Pfizer
|
8/30/2011 | SP | Credit Suisse to price capped knock-out notes on Pfizer via JPMorgan
|
8/30/2011 | SP | New Issue: Deutsche Bank prices $531,000 knock-out notes on Pfizer via JPMorgan
|
8/23/2011 | SP | Deutsche to price knock-out notes linked to Pfizer via JPMorgan
|
8/16/2011 | SP | New Issue: JPMorgan prices $4.06 million 7.5% trigger yield optimization notes on Pfizer
|
8/15/2011 | SP | New Issue: UBS prices $114,500 trigger phoenix autocallables linked to Pfizer
|
8/15/2011 | SP | New Issue: UBS prices $105,000 trigger phoenix autocallables linked to Pfizer
|
8/10/2011 | SP | JPMorgan plans 6.6%-8.6% trigger yield notes linked to Pfizer
|
7/7/2011 | IG | Moody's: Pfizer unchanged
|
6/24/2011 | SP | New Issue: RBC prices $3.95 million trigger phoenix autocallables linked to Pfizer
|
6/20/2011 | SP | RBC plans trigger phoenix autocallables linked to Pfizer stock
|
5/3/2011 | SP | New Issue: JPMorgan prices $10.48 million daily observation knock-out notes tied to Pfizer
|
3/1/2011 | CVLM | King Pharmaceuticals holders put $397.31 million 1.25% convertibles
|
1/31/2011 | CVLM | King tenders for all $400 million of 1.25% convertible notes due 2026
|
12/23/2010 | SP | New Issue: Credit Suisse prices $820,000 contingent coupon autocallable notes on five stocks
|
12/17/2010 | SP | Credit Suisse plans contingent coupon callable notes on five stocks
|
11/16/2010 | SP | New Issue: JPMorgan prices $3.55 million capped daily observation knock-out notes on Pfizer
|
11/9/2010 | SP | JPMorgan plans capped daily observation knock-out notes on Pfizer
|
11/9/2010 | SP | New Issue: JPMorgan prices $10.55 million capped daily observation knock-out notes linked to Pfizer
|
11/2/2010 | SP | JPMorgan plans capped daily observation knock-out notes on Pfizer
|
10/21/2010 | SP | New Issue: JPMorgan sells $8.4 million daily observation knock-out notes linked to Pfizer
|
10/19/2010 | SP | New Issue: JPM prices $5.2 million daily observation knock-out notes on Pfizer
|
10/12/2010 | IG | Fitch: Pfizer unaffected
|
10/4/2010 | IG | Fitch: Pfizer view to negative
|
9/22/2010 | SP | New Issue: HSBC prices $2 million knock-out buffer notes on Pfizer via JPMorgan
|
9/20/2010 | SP | New Issue: Barclays prices $9.82 million 7.5% yield optimization notes on Pfizer via UBS
|
9/3/2010 | SP | Barclays to price 7.5%-10% yield optimization notes linked to Pfizer
|
8/30/2010 | SP | New Issue: Bank of America sells $10.51 million step up notes tied to Pfizer stock
|
8/25/2010 | SP | New Issue: Barclays prices $500,000 9% reverse convertibles linked to Pfizer
|
8/10/2010 | SP | Bank of America plans to price step up notes linked to Pfizer
|
7/26/2010 | SP | New Issue: JPMorgan prices $575,000 daily observation knock-out notes linked to Pfizer
|
7/21/2010 | SP | New Issue: JPMorgan prices $4.21 million daily observation knock-out notes linked to Pfizer
|
5/28/2010 | SP | New Issue: UBS prices $6.28 million 10.3% yield optimization notes linked to Pfizer
|
5/20/2010 | SP | UBS to price 7.5%-10% yield optimization notes linked to Pfizer
|
2/26/2010 | SP | New Issue: Wells Fargo sells $1.14 million enhanced growth notes tied to Pfizer for Eksportfinans
|
2/10/2010 | SP | Wells Fargo to price enhanced growth securities linked to Pfizer for Eksportfinans
|
2/4/2010 | IG | Market Commentary: Kraft, Berkshire, Pacific Life sell nearly $18 billion in bonds; Kraft tighter in trading
|
1/5/2010 | IG | Market Commentary: Foreigners Dexia, Barclays, Lloyds, KfW tap market, GE Capital lone domestic; spreads tighten
|
12/31/2009 | IG | Outlook 2010: Drug companies, money managers lead 2009's notable deals
|
12/24/2009 | IG | Market Commentary: New deals continue hiatus; financials active in trading, others quiet
|
10/30/2009 | IG | Pfizer announces successful consent solicitation for Wyeth notes
|
10/20/2009 | IG | Market Commentary: Citi sells FDIC notes, JPMorgan, Meccanica, KBN offer bonds; new JPMorgan active
|
10/20/2009 | IG | Market Commentary: Citi sells FDIC notes, JPMorgan, Meccanica, KBN offer bonds; new JPMorgan active
|
10/19/2009 | IG | Market Commentary: Southern, Temasek, Santander US Debt sell notes; secondary volume fades; investors eye EM
|
10/16/2009 | IG | Pfizer solicits consents to amend several series of Wyeth notes
|
10/16/2009 | IG | S&P lowers Pfizer, lifts Wyeth
|
10/16/2009 | IG | Moody's keeps Wyeth on review
|
10/16/2009 | IG | Market Commentary: B of A bonds widen; GE Capital unmoved on earnings; industrial trading null on bank focus
|
10/15/2009 | IG | Moody's lowers Pfizer, keeps Wyeth on review
|
10/15/2009 | IG | Fitch cuts Pfizer, ups Wyeth
|
10/15/2009 | SS | Pfizer completes cash-and-stock acquisition of Wyeth
|
10/14/2009 | SS | Market Commentary: Pfizer to close on Wyeth acquisition; Aquiline OKs bid; Redstone keeps control of CBS, Viacom
|
9/30/2009 | SS | Market Commentary: Kraft likely to keep mum until deadline; CIT shares sink; Analyst: MSC bids nearing ceiling
|
9/25/2009 | SS | Market Commentary: Kraft's chances of Cadbury takeover viewed as high; Pfizer could take hit on Japanese deal
|
9/23/2009 | SS | Market Commentary: Cadbury move may limit investors; quick deal OK likely for Wyeth; bid sends SkyTerra shares up
|
7/24/2009 | IG | Market Commentary: Primary empties, coming week seen busier; Boeing, Bank of America unchanged, St. Jude gains
|
7/20/2009 | SS | Market Commentary: China may OK Wyeth deal by fall; Addax stock sale sparks concern; Dioro, Northgate in talks
|
7/20/2009 | SS | Wyeth shareholders agree to Pfizer merger; deal to close by year-end
|
7/17/2009 | SS | Market Commentary: China extends review of Pfizer deal; British life insurer in combo talks; CIT shares soar
|
7/17/2009 | SS | Pfizer gets European Commission clearance for acquisition of Wyeth
|
7/1/2009 | SS | Market Commentary: Wyeth buyout expected to clear foreign reviews; Emulex, IPC get slim chances for other bids
|
6/25/2009 | IG | Market Commentary: Citigroup, Jefferies, Analog Devices, MassMutual, Torchmark sell notes; Merck busy, up again
|
6/18/2009 | SS | Market Commentary: WebMD plans merger with HLTH; Broadcom again extends tender offer; Wyeth sets vote date
|
6/17/2009 | SS | Wyeth shareholders to decide Pfizer merger at meeting on July 20
|
5/27/2009 | IG | Moody's rates Pfizer's notes Aa2
|
5/27/2009 | IG | S&P rates Pfizer notes AAA
|
5/26/2009 | IG | Fitch assigns Pfizer notes AA
|
4/15/2009 | SP | New Issue: RBC prices $0.09 million 12% reverse convertibles linked to Pfizer
|
4/13/2009 | IG | Market Commentary: Portland General Electric, California Water, Toll sell bonds; Portland General firms in trading
|
4/7/2009 | SS | Market Commentary: Spread widens on Wyeth stock; Biogen jumps on buyout talk; Cubist makes difficult takeover target
|
4/6/2009 | IG | Market Commentary: ConAgra, Hutchison Whampoa sell bonds; Suncorp-Metway, Ventas plan deals; secondary tightens
|
4/3/2009 | IG | Market Commentary: New Energy Transfer Partners bonds firm smartly, TJX still trading tight; primary activity seen muted
|
4/3/2009 | SS | Pfizer responds to FTC, says merger with Wyeth remains on track
|
4/2/2009 | SP | RBC to price 12% RevCons linked to Pfizer
|
3/31/2009 | IG | Market Commentary: GE Capital prices $975 million FDIC deal; Ingersoll-Rand brings $655 million; spreads wider; Pfizer active
|
3/30/2009 | IG | Market Commentary: PNC brings $1 billion in FDIC-backed bonds; Ingersoll-Rand plans benchmark; spreads wider
|
3/27/2009 | IG | Market Commentary: Bank of New York Mellon, U.S. Bancorp, Morgan Stanley sell FDIC deals; B of A, Merrill widen
|
3/26/2009 | IG | Market Commentary: World Bank, Newell Rubbermaid, Sunoco, Berkshire Hathaway sell bonds; spread widen; John Deere gains
|
3/25/2009 | IG | Market Commentary: Wells Fargo, Lloyds TSB Bank, John Deere Capital, Idaho Power sell bonds; spreads tighter; Pfizer in demand
|
3/24/2009 | IG | Market Commentary: Bacardi, Verizon, Staples sells bonds as tone remains up; Time Warner Cable, Con Ed, Illinois Tool firm
|
3/23/2009 | IG | Market Commentary: Time Warner, Atmos, ConEd, Northwestern Energy, Praxair, Illinois Tool sells bonds; spreads tighten
|
3/20/2009 | IG | Market Commentary: Simon Property, Empire District Electric, Northwest Natural Gas price; Pfizer bonds popular
|
3/20/2009 | IG | Market Commentary: Simon Property, Empire District Electric, Northwest Natural Gas price; Pfizer bonds popular
|
3/19/2009 | IG | Market Commentary: UPS, Kansas City Power, Barrick Gold, Peco Energy price deals; spreads tighten, Shell bond widens
|
3/19/2009 | SP | RBC to price 9.5% reverse convertibles linked to Pfizer
|
3/18/2009 | IG | Market Commentary: Shell, BHP Billiton, Duke Energy units, Marsh & McLennan sell bonds; Pfizer gains in secondary
|
3/17/2009 | HY | Market Commentary: Wynn stock sale boosts bonds; Sprint gains continue; GM up further; MGM posts loss, gets waiver
|
3/17/2009 | IG | New Issue: Pfizer prices $13.5 billion of notes in five tranches
|
3/17/2009 | IG | Fitch gives Pfizer notes AA
|
3/17/2009 | IG | Market Commentary: Pfizer sells $13.5 billion bond issue; State Street, SoCal Edison price; Pfizer bonds tighten
|
3/17/2009 | SS | Market Commentary: Wyeth shares play catch-up to Pfizer bid; Exelon, NRG spar; Merck, Schering-Plough timing eyed
|
3/16/2009 | HY | Market Commentary: Sprint shrugs off stock downgrade, slide; GM keeps cruising; Charter a champ, Momentive massacred
|
3/16/2009 | IG | Pfizer to sell up to $10 billion of notes in five tranches, gives guidance: sources
|
3/16/2009 | IG | S&P rates Pfizer notes AAA
|
3/16/2009 | IG | Market Commentary: Pfizer plans mega deal; Progress Energy, Smith International sell bonds; financials tighten
|
3/11/2009 | IG | Moody's lowers Pfizer
|
2/25/2009 | SP | New Issue: ABN Amro prices $0.1 million 12.5% reverse convertibles linked to Pfizer
|
2/13/2009 | SP | New Issue: RBC prices $0.025 million 10% reverse convertibles linked to Pfizer
|
2/11/2009 | SP | ABN Amro to price 12.5% reverse exchangeables linked to Pfizer
|
2/3/2009 | SP | RBC to price 10% reverse convertibles linked to Pfizer
|
1/30/2009 | SS | Market Commentary: Genentech bid lacks support; Wyeth buyout includes hefty breakup fees; Exelon moves for NRG control
|
1/29/2009 | SS | Market Commentary: Whole Foods moves to settle with FTC; Amylin sale not expected in Icahn's wake; Wyeth shares fall
|
1/26/2009 | SS | Pfizer to acquire Wyeth for $68 billion
|
1/26/2009 | SS | Market Commentary: Market doubts Pfizer, Wyeth deal; Dow gets court action from Rohm & Haas; Quiksilver up on sale talk
|
1/26/2009 | IG | S&P: Pfizer on watch
|
1/26/2009 | IG | Moody's may cut Pfizer
|
1/26/2009 | IG | Fitch drops Pfizer
|
1/26/2009 | IG | Market Commentary: Primary's slow pace of issuance continues; Caterpillar, Pfizer bonds weaker, McDonald's better
|
1/23/2009 | SS | Market Commentary: Interwoven bid likely all investors will get; closing concerns widen spread on American Land Lease stock
|
1/21/2009 | SP | RBC to price 12.5% RevCons linked to Pfizer
|
1/13/2009 | SS | Market Commentary: Elan moves closer to sale block; second bid for Genentech expected; Puget trades at discount to deal
|
1/9/2009 | SS | Market Commentary: Analyst sees Elan, Pfizer combo unlikely; DOJ studies Centennial buyout; Crucell moves on deal talk
|
1/5/2009 | SS | Market Commentary: Dow could close on Rohm & Haas; Pfizer looks for targets; Borders, Tyson make leadership changes
|
12/31/2008 | SP | New Issue: Barclays prices $2 million 9.5% reverse convertibles linked to Pfizer
|
12/31/2008 | SS | Pfizer's tender offer for Coley ends; merger expected to close within days
|
12/19/2008 | IG | Fitch affirms Pfizer
|
11/12/2008 | SP | Barclays to price 10% reverse convertibles linked to Pfizer
|
11/12/2008 | SP | RBC plans 12.8% reverse convertibles linked to Pfizer
|
11/10/2008 | SP | New Issue: RBC sells $1.25 million 14.5% reverse convertibles linked to Pfizer
|
11/3/2008 | SP | RBC plans 14.5% reverse convertibles linked to Pfizer
|
10/30/2008 | SP | New Issue: RBC prices $0.021 million 11.25% reverse convertibles linked to Pfizer
|
10/14/2008 | SP | RBC plans 11.25% reverse convertibles linked to Pfizer
|
9/29/2008 | SP | New Issue: ABN Amro prices $0.7 million 10% reverse convertibles linked to Pfizer
|
9/29/2008 | SP | New Issue: Barclays prices $3.5 million 9.25% reverse convertibles linked to Pfizer
|
9/26/2008 | SP | New Issue: ABN Amro prices $0.25 million 11% reverse convertibles linked to Pfizer
|
9/23/2008 | SP | ABN Amro to price 10% reverse exchangeables linked to Pfizer
|
9/11/2008 | SP | Barclays to price 9.25% reverse convertibles linked to Pfizer
|
9/9/2008 | SP | ABN Amro plans 11% knock-in notes linked to Pfizer
|
9/9/2008 | SP | New Issue: Barclays prices $2 million 8.75% reverse convertibles linked to Pfizer
|
9/2/2008 | IG | Market Commentary: KfW, AmEx Credit price notes, BB&T plans trust preferred issue; secondary tone slides late in day
|
8/29/2008 | SP | Barclays to price 8.75% reverse convertibles linked to Pfizer
|
7/30/2008 | SP | New Issue: ABN Amro prices $1 million 12.1% reverse convertibles linked to Pfizer
|
7/30/2008 | SP | New Issue: Barclays prices $1.5 million 8.5% reverse convertibles linked to Pfizer
|
7/11/2008 | SP | Barclays to price 8.5% reverse convertibles linked to Pfizer
|
6/27/2008 | SP | New Issue: ABN Amro prices $150,000 10% reverse convertibles linked to Pfizer
|
6/27/2008 | SP | New Issue: Barclays prices $6 million 8.75% reverse convertibles linked to Pfizer
|
6/11/2008 | SP | ABN Amro plans 10% knock-in notes linked to Pfizer
|
6/10/2008 | SP | Barclays to price 8.75% reverse convertibles linked to Pfizer
|
6/10/2008 | SS | Encysive Pharmaceuticals becomes wholly owned subsidiary of Pfizer
|
6/4/2008 | SS | Market Commentary: Verizon heard to be in talks with Alltel; Icahn plans Microsoft's return; Lehman fights sale rumors
|
5/20/2008 | SP | Barclays to price 9.5% reverse convertibles linked to Pfizer
|
5/7/2008 | SP | Fortis to price 17.25% knock-in reverse convertibles linked to worst of 'Small Dogs' basket
|
4/30/2008 | SP | New Issue: ABN Amro prices $0.95 million 10% reverse convertibles linked to Pfizer
|
4/21/2008 | IG | Moody's gives Pfizer loan Aa1
|
4/15/2008 | SS | Pfizer completes subsequent tender offer for Encysive shares; $195 million merger nears completion
|
4/8/2008 | SS | Pfizer extends subsequent offering period for Encysive
|
4/7/2008 | SP | ABN Amro plans 10% reverse exchangeables linked to Pfizer
|
4/7/2008 | SS | Pfizer's subsequent offer for remaining Encysive shares ends Monday
|
4/1/2008 | SS | Pfizer subsidiary acquires 86.8% of Encysive's shares through tender offer, begins subsequent offer
|
3/28/2008 | SP | New Issue: ABN Amro prices $3.2 million 9.75% reverse convertibles linked to Pfizer
|
3/28/2008 | SP | New Issue: Barclays prices $4 million 9.125% reverse convertibles linked to Pfizer
|
3/28/2008 | SP | New Issue: JPMorgan prices $345,000 9% reverse exchangeables linked to Pfizer
|
3/12/2008 | SP | JPMorgan to price 9% reverse exchangeables linked to Pfizer
|
3/11/2008 | SP | Barclays to price 9.125% reverse convertibles linked to Pfizer
|
3/11/2008 | SP | JPMorgan cuts coupon on reverse exchangeables linked to Pfizer
|
3/10/2008 | SP | JPMorgan to price 10% reverse exchangeables linked to Pfizer
|
3/4/2008 | SP | ABN Amro plans 9.75% Knock-in Reverse Exchangeables linked to Pfizer
|
3/4/2008 | SS | Pfizer begins tender offer for Encysive
|
2/28/2008 | SP | New Issue: JPMorgan prices $904,000 9% reverse exchangeables linked to Pfizer
|
2/27/2008 | SP | New Issue: RBC prices $1 million 11.5% RevCons linked to Pfizer
|
2/20/2008 | SS | Market Commentary: Pfizer doubles Encysive share price; line is dead for 3Com; Microsoft hires proxy muscle
|
2/20/2008 | SS | Pfizer expects to boost revenue from European market with $195 million acquisition of Encysive
|
2/15/2008 | SP | New Issue: ABN Amro prices $1.1 million 8% reverse convertibles linked to Pfizer
|
2/11/2008 | SP | JPMorgan to price 9% reverse exchangeables linked to Pfizer
|
2/4/2008 | SP | Lehman plans annual review notes linked to Pfizer
|
12/18/2007 | SS | Pfizer, Coley merger clears waiting period, regulatory hurdle
|
12/14/2007 | SP | New Issue: ABN Amro prices $500,000 8.1% reverse exchangeables linked to Pfizer
|
12/12/2007 | IG | Fitch drops Pfizer
|
12/10/2007 | SP | Barclays to price 9.5% reverse convertibles linked to Pfizer
|
12/7/2007 | IG | Fitch rates Pfizer notes AAA
|
12/7/2007 | IG | Moody's rates Pfizer notes Aa1
|
12/7/2007 | IG | S&P rates Pfizer notes AAA
|
11/30/2007 | SS | Pfizer begins tender for Coley Pharmaceutical shares
|
11/29/2007 | SP | New Issue: Barclays prices $3 million 9.75% reverse convertibles linked to Pfizer
|
11/29/2007 | SP | New Issue: Lehman sells $709,000 of 9.5% reverse exchangeables linked to Pfizer
|
11/16/2007 | SS | Pfizer to broaden research with acquisition of Coley Pharmaceutical
|
11/16/2007 | SS | Market Commentary: Coley zooms on Pfizer buyout plan; Schering-Plough climbs; AMD down after Mubadala stock purchase
|
11/8/2007 | SP | Barclays to price 9.75% reverse convertibles linked to Pfizer
|
11/7/2007 | SP | Lehman plans 9.5% reverse exchangeables linked to Pfizer
|
10/30/2007 | SP | New Issue: Barclays prices $1.5 million 10.25% reverse convertibles linked to Pfizer
|
10/29/2007 | SP | New Issue: UBS prices $7.94 million 8.85% yield optimization notes linked to Pfizer
|
10/19/2007 | IG | Moody's cuts Pfizer view to negative
|
10/15/2007 | SP | New Issue: ABN Amro prices $2.6 million 8.75% reverse convertibles linked to Pfizer
|
10/10/2007 | SP | Barclays to price 10.25% reverse convertibles linked to Pfizer
|
9/27/2007 | SP | New Issue: JPMorgan prices $950,000 12.5% notes linked to least-performing stock in basket
|
9/24/2007 | SP | UBS to price yield optimization notes linked to Pfizer
|
8/31/2007 | SP | New Issue: Barclays prices $3 million 9.75% reverse convertibles linked to Pfizer
|
8/30/2007 | SP | New Issue: RBC prices $1.78 million 8% reverse convertibles linked to Pfizer
|
8/29/2007 | SP | New Issue: ABN Amro sells $800,000 9% Knock-in Reverse Exchangeables linked to Pfizer
|
8/27/2007 | SP | New Issue: RBC sells $1 million 11% reverse convertibles linked to Pfizer
|
8/21/2007 | SP | New Issue: Citigroup sells $18 million 2.8% exchangeable notes linked to Pfizer
|
8/8/2007 | SP | RBC to price 8% reverse convertibles linked to Pfizer
|
8/8/2007 | SP | Barclays to price 9.75% reverse convertibles linked to Pfizer
|
8/6/2007 | SP | Eksportfinans to price 9.05% reverse convertibles linked to Pfizer
|
8/2/2007 | SP | ABN Amro plans 9% Knock-in Reverse Exchangeables linked to Pfizer
|
7/27/2007 | SP | New Issue: ABN sells $7.725 million 9.3% reverse convertibles linked to Pfizer
|
7/6/2007 | SP | ABN Amro plans 9.3% knock-in notes linked to Pfizer
|
7/3/2007 | SP | ABN Amro plans 9.3% reverse exchangeable securities linked to Pfizer
|
6/29/2007 | SP | New Issue: JPMorgan prices $1 million 10% reverse exchangeables linked to Pfizer
|
6/26/2007 | SP | JPMorgan to price 10% reverse exchangeables linked to Pfizer
|
6/12/2007 | SS | Pfizer granted 30-day discovery on claims it is delaying Quigley bankruptcy case
|
6/11/2007 | SS | Market Commentary: Medivation spikes; H&R Block props up Jackson Hewitt, Intuit; Ford up; Affiliated Computer up
|
4/27/2007 | SP | New Issue: RBC sells $1.058 million 8.6% reverse convertibles linked to Pfizer
|
4/26/2007 | SS | Market Commentary: Nacco oscillates; Wendy's gains; Applebee's rises; Biosite bows; Harman up; new Delta slow, low
|
4/19/2007 | SP | RBC to price 8.6% reverse convertibles linked to Pfizer
|
4/4/2007 | SP | ABN Amro to price 11% knock-in notes linked to Pfizer
|
4/3/2007 | SP | Rabo to price 8.6% knock-in reverse convertibles linked to Pfizer via LaSalle
|
3/30/2007 | CV | Pfizer files debt securities, stock shelf
|
1/22/2007 | SS | Market Commentary: CANTV crashes; Pfizer falls; Gap gapes; Movie Gallery whipsawed; Swift driven up; Citigroup cheered
|
12/29/2006 | SP | New Issue: ABN Amro sells $2.55 million 9.25% Knock-in Reverse Exchangeables linked to Pfizer
|
12/15/2006 | SP | New Issue: Barclays sells $1.5 million 8.5% reverse convertibles linked to Pfizer
|
12/4/2006 | SS | Merger plans push Bank of New York, Mellon higher; LSI off on Agere union; Stations up on LBO
|
12/4/2006 | SP | ABN Amro to issue 9.25% Knock-In Reverse Exchangeables linked to Pfizer
|
10/23/2006 | BT | Pfizer kept at outperform by Bear Stearns
|
10/19/2006 | BT | Pfizer plans transformation following strong third quarter
|
10/19/2006 | BT | Market Commentary: Asthmatx on deck; Ariad slides after-hours; Siga slips on PIPE; Accentia rises 42% on trial data
|
10/18/2006 | BT | Pfizer gets outperform from Bear Stearns
|
9/26/2006 | BT | Pfizer expands ophthalmology research through deal with Quark
|
9/20/2006 | BT | Pfizer pledges $15 million to Clinton's Global Initiative for malaria
|
9/18/2006 | BT | Pfizer pays $155 million for TransTech's Alzheimer's compounds
|
9/18/2006 | BT | Pfizer's Lyrica gets European approval for nerve pain
|
9/14/2006 | BT | Pfizer: Exubera effective in diabetics exposed to cigarette smoke
|
9/13/2006 | BT | Pfizer's Lipitor patent upheld in Dutch court
|
9/6/2006 | BT | Pfizer: data show Lipitor cuts heart attack risk more than simvastatin
|
9/6/2006 | BT | Pfizer: Study shows amlodipine lowers blood pressure, cuts diabetes risk
|
9/5/2006 | BT | Pfizer provides $2 million grant for cancer research
|
9/1/2006 | BT | Pfizer wins Norvasc patent challenge by Synthon
|
8/17/2006 | BT | Pfizer does not infringe Synthon IP patent for amlodipine process, jury rules unanimously
|
8/9/2006 | BT | Pfizer's Lipitor curbs repeat strokes by 16%, major coronary events by 35%, data shows
|
8/3/2006 | BT | Pfizer reiterated at outperform by Bear Stearns
|
8/2/2006 | BT | Novo Nordisk: lawsuit claims Pfizer infringes inhaled insulin treatment patent
|
8/2/2006 | BT | Pfizer, Ranbaxy: both sides win one part of patent lawsuit for atorvastatin
|
7/28/2006 | BT | Pfizer receives positive opinion from CHMP for its smoking cessation pill Champix
|
7/28/2006 | BT | Pfizer names Jeffrey Kindler new CEO
|
7/20/2006 | BT | Pfizer's second-quarter revenues up 3% to $11.74 billion
|
7/20/2006 | BT | Market Commentary: Amgen weakens; Gilead off 3%; Alfacell falls 30%; Nektar up; Accentia lower; Connetics lifted
|
7/13/2006 | BT | S&P: Pfizer, Merck likely unchanged
|
7/7/2006 | BT | Fitch affirms Pfizer IDR at AAA
|
7/5/2006 | BT | Pfizer: Data show Chantix provides smokers new tool to quit smoking
|
7/5/2006 | BT | Market Commentary: DOV seesaws on CEO exit, closes higher; Neurocrine slides further; Insmed drops 8%; Tercica off 1%
|
7/3/2006 | BT | Market Commentary: Encore cheered as it goes private on Blackstone buyout at a 36% premium; Siemens, Bayer up
|
6/28/2006 | BT | Pfizer patent for Lipitor ingredient upheld in British court
|
6/26/2006 | BT | Moody's affirms Pfizer
|
6/26/2006 | BT | Market Commentary: Vasogen plunges 74%; Anadys falls 45%; Nastech, Amylin gain on pact; Neurocrine finds buyers
|
6/26/2006 | BT | Johnson & Johnson to acquire Pfizer Consumer Healthcare for $16.6 billion in cash
|
6/26/2006 | BT | OSI, Pfizer start phase 4 trial of Macugen for age-related macular degeneration
|
6/26/2006 | BT | S&P: Pfizer unchanged
|
6/23/2006 | BT | Market Commentary: Neurocrine, DOV fall on Pfizer nixing indiplon funding; Endo rises 10%, Penwest gains 37%
|
6/22/2006 | BT | Neurocrine, Pfizer end collaboration on indiplon, Neurocrine to develop independently
|
6/19/2006 | BT | Market Commentary: Peregrine up; Micrus off; DOV drops 11%; Neurocrine off 7%; American Medical plans $325 million bond
|
6/14/2006 | BT | Pfizer to use Bayer compound to develop potential obesity, diabetes treatments
|
6/12/2006 | BT | Pfizer reports long-term data from phase 3 trials support long-term efficacy, safety of Exubera for diabetes
|
6/5/2006 | BT | Pfizer reports switching to Aromasin from tamoxifen improves survival for women with early breast cancer
|
6/2/2006 | BT | Market Commentary: Encysive stock skyrockets on nod from European agency; Alphatec stock slips on IPO
|
5/16/2006 | BT | Market Commentary: Neurocrine, DOV dive; Novavax, Generex dive amid noise of exits; Adventrx slips modestly on deal
|
5/15/2006 | BT | Pfizer's Lipitor reduces heart attack, stroke more than Zocor, economic study says
|
5/15/2006 | BT | Market Commentary: BioMimetic goes south; Sirna off on new deal; Cambridge rockets on buyout; Threshold extends fall
|
5/11/2006 | BT | Pfizer smoking-cessation drug wins FDA approval
|
5/8/2006 | BT | Pfizer, Monogram to make HIV co-receptor tropism test available globally
|
5/3/2006 | BT | Market Commentary: MGI, SuperGen get nod from FDA for Dacogen; Impax stock climbs on FDA OK of generic Colestid
|
4/28/2006 | BT | Pfizer's Sutent for two cancer types approved for conditional marketing in European Union
|
4/25/2006 | BT | Ranbaxy wins atorvastatin suit in Austria; Pfizer to defend Lipitor patent in other countries
|
4/25/2006 | BT | Market Commentary: Serologicals, Millipore both up; other services names dip; DOV, Discovery dive; Neurocrine off
|
4/20/2006 | BT | Moody's affirms Pfizer
|
4/20/2006 | BT | Pfizer rated at outperform by Bear Stearns
|
4/19/2006 | BT | Pfizer reports increase in first-quarter net income, Lipitor sales
|
4/13/2006 | BT | Pfizer acquires rights to drug candidate fesoterodine for overactive bladder
|
4/6/2006 | BT | Pfizer acquires Rinat Neuroscience
|
4/3/2006 | BT | Pfizer study suggests that Celebrex may stop tumor growth
|
3/28/2006 | BT | Immunicon, Pfizer expand clinical research, development agreement
|
3/27/2006 | BT | Pfizer's Lyrica approved for anxiety disorder treatment in Europe
|
3/24/2006 | BT | Market Commentary: BioMarin shares, new bonds gain; Cephalon loses 13%; Idenix falls 28%; King slips; Encysive declines
|
3/23/2006 | BT | Pfizer licenses NOX-B11 Spiegelmer technology to develop obesity treatment
|
3/14/2006 | BT | Pfizer says torcetrapib/atorvastatin raises 'good,' lowers 'bad' cholesterol
|
3/13/2006 | BT | Pfizer says Lipitor improves kidney function in heart disease patients
|
2/24/2006 | BT | OSI, Pfizer three-year trial data review shows Macugen safe
|
2/21/2006 | BT | FDA approves Pfizer's Eraxis for candidemia bloodstream infection
|
2/17/2006 | BT | New Issue: Pfizer ¥60 billion five-year bond yields 1.2007%; ¥55 billion 10 year yields 1.808%
|
2/17/2006 | BT | Market Commentary: Cytyc shares, convertibles gain big; Alkermes slips on FDA news; NPS Pharma off amid uncertainty
|
2/15/2006 | BT | Pfizer to sell ¥50 billion of bonds Thursday via Mitsubishi UFJ, Goldman, Citi
|
2/15/2006 | BT | Market Commentary: Pfizer peddling ¥50 billion bonds; Amgen up out of chute; Adolor at bat; Ranbaxy taps convertibles market
|
2/14/2006 | BT | Moody's rates Pfizer notes Aaa
|
2/14/2006 | BT | S&P rates Pfizer notes AAA
|
2/13/2006 | BT | Bear Stearns puts Pfizer at outperform
|
2/10/2006 | BT | Pfizer forecasts strong growth for key medicines, expects six new medicines this year
|
2/10/2006 | BT | Market Commentary: Acorda shares close up 12%; Shire better, other ADHD names off on drug labeling; Pfizer slides
|
2/9/2006 | BT | Bear Stearns gives Pfizer outperform rating
|
2/9/2006 | BT | Teva calls Pfizer patent violation allegations 'baseless'
|
2/8/2006 | BT | Pfizer asks FDA to recall Teva, Sandoz generic azithromycin
|
2/8/2006 | BT | Market Commentary: Pfizer news sparks buyout buzz; Immtech falls; Alkermes up; Icos off; Alexion higher; Oscient down
|
2/7/2006 | BT | Pfizer to consider spinning off or selling consumer healthcare business
|
2/7/2006 | BT | Oscient, Pfizer enter agreement for Factive tablets in Mexico
|
2/2/2006 | BT | Pfizer, OSI Pharmaceuticals' Macugen approved for treatment of macular degeneration in Europe
|
1/27/2006 | BT | Market Commentary: Arena up after follow-on; Altus interest grows; Nektar, Pfizer up; Glaxo gains on Gates' TB pledge; Teva prices
|
1/27/2006 | BT | Pfizer receives FDA approval for Exubera inhalable insulin for diabetes
|
1/27/2006 | BT | Pfizer's Lyrica gets positive opinion from European Medicines Agency committee
|
1/26/2006 | BT | Pfizer's Exubera inhalable insulin for diabetes approved by European Commission
|
1/20/2006 | BT | Pfizer reiterated by Bear Stearns at outperform
|
1/19/2006 | BT | Market Commentary: Endo Pharmaceuticals prices $417.75 million secondary stock sale; Procyon to merge with Cellpep
|
1/13/2006 | BT | Market Commentary: Nektar up over 10% on Pfizer's move; Encysive, Alexion up big; Biopure loses 4% after follow-on
|
1/12/2006 | BT | Pfizer pays $1.3 billion to acquire rights to inhaled human insulin from sanofi
|
1/9/2006 | BT | Chromos, Pfizer expand cell line collaboration
|
1/5/2006 | BT | Bear Stearns reiterates Pfizer at outperform
|
1/4/2006 | BT | Pfizer, Sangamo expand collaboration on research of enhanced protein production
|
12/30/2005 | BT | Pfizer buys $50 million in Perlegen Sciences preferreds, gaining 12% stake
|
12/21/2005 | BT | Pfizer gets priority review from FDA for Champix anti-smoking medicine
|
12/19/2005 | BT | Market Commentary: Pfizer, other Big Pharmas zoom; generic names Barr, Teva plunge; Cubist, Rigel, Xoma, Lexicon off
|
12/19/2005 | BT | Tripos announces job layoffs as four-year Pfizer contract ends
|
12/19/2005 | BT | Pfizer reiterated by Bear Stearns at market outperform
|
12/15/2005 | BT | CogState signs A$1.28 million deal with Pfizer to support development of cognitive tests
|
12/15/2005 | BT | Moody's affirms Pfizer
|
12/13/2005 | BTCV | New Issue: ABN Amro sells $1.8 million 9.25% reverse exchangeables linked to Pfizer
|
12/12/2005 | BT | S&P: Pfizer unaffected
|
12/12/2005 | BT | Pfizer ups dividend 26%
|
12/7/2005 | BT | Pfizer study shows switching to Aromasin after tomoxifen is cost-effective treatment for breast cancer patients
|
11/28/2005 | BT | Coley, Pfizer begin phase 3 trials of PF-3512676 for lung cancer
|
11/23/2005 | BT | Tripos may need to reduce staff after Pfizer ends four-year, $90 million research collaboration
|
11/22/2005 | BT | Moody's rates Pfizer Investment notes Aaa
|
11/22/2005 | BT | Pfizer exercises option to develop NicOx ophthalmology compound
|
11/22/2005 | BT | Moody's assigns negative outlook to pharmaceutical industry
|
11/21/2005 | BTPP | Pfizer, Incyte establish license agreement for CCR2 antagonists; Incyte may gain $783 million
|
11/18/2005 | BT | S&P rates Pfizer notes AAA
|
11/18/2005 | BTCV | New Issue: ABN Amro sells $1.46 million 9.5% Knock-In Reverse Exchangeables linked to Pfizer
|
11/16/2005 | BT | Pfizer says study finds Revatio effective in treating pulmonary arterial hypertension
|
11/15/2005 | BT | Pfizer says its anti-smoking medication is more effective than current treatment
|
11/15/2005 | BT | Pfizer's torcetrapib/atorvastatin raises good cholesterol, cuts bad cholesterol, study funds
|
11/14/2005 | BT | Pfizer study shows Norvasc lowers central arterial blood pressure
|
10/31/2005 | BT | Pfizer receives approval for Zeldox in Europe to treat bipolar disorder
|
10/28/2005 | BTCV | New Issue: Barclays sells $3 million 9.25% exchangeables linked to Pfizer
|
10/28/2005 | BT | Exubera FDA review pushed back, says Pfizer and sanofi-aventis
|
10/24/2005 | BT | Market Commentary: Roche, Gilead gain on flu talks; niche flu names higher as well; Schering, Wyeth, Pfizer watched
|
10/18/2005 | BT | Moody's affirms Pfizer
|
10/12/2005 | BT | Market Commentary: Vical falls 20% on PIPEs deal; Threshold, Dynavax off on stock sales; Pharma Product higher
|
9/29/2005 | BTCV | New Issue: Eksportfinans prices $655,000 notes linked to Pfizer
|
9/13/2005 | BT | Pfizer maintained by Bear Stearns at outperform
|
9/7/2005 | BT | Market Commentary: ID Biomedical climbs 13% on Glaxo acquisition; Chiron still rising; Nektar zooms over 10%
|
8/29/2005 | BT | Market Commentary: AtheroGenics, Amylin Pharma, Alpharma extend gains on takeover chatter; Pfizer, Merck credit mixed
|
8/19/2005 | BT | Market Commentary: Quintiles tapping bond market for $150 million; Merck spirals on Vioxx verdict; Vyteris taps PIPEs
|
8/1/2005 | BT | Market Commentary: Anadys, Ariad, Nastech offerings join ZymoGenetics for this week; Amgen, Abgenix up on fast track
|
6/23/2005 | BT | Pfizer to buy back $5 billion of shares
|
6/23/2005 | BT | Market Commentary: Forest Labs up sharply; King sees buying; Avalon sets IPO range; Salix dives; Xoma, ViaCell bounce
|
6/17/2005 | BT | Fitch affirms Pfizer
|
6/16/2005 | BT | Pfizer purchases Vicuron Pharmaceuticals for $1.9 billion cash
|
3/9/2005 | CV | New Issue: Goldman Sachs prices $20 million 4.8% trigger notes exchangeable for Pfizer
|
3/9/2005 | CV | New Issue: Goldman Sachs prices $20 million 5.45% trigger notes exchangeable for Pfizer
|
3/7/2005 | DD | Quigley's plan of reorganization calls for Pfizer to contribute $405 million to asbestos injury trust
|
2/7/2005 | CV | New Issue: Goldman Sachs prices $10.84 million 5.9% trigger notes exchangeable for Pfizer
|
10/1/2004 | CV | New Issue: Barclays sells $1.6 million 7% reverse exchangeables linked to Pfizer
|
9/3/2004 | DD | Pfizer negotiates $430 million settlement over asbestos claims
|
10/28/2003 | CV | New Issue: UBS prices $1.14 million 0% notes linked to Pfizer
|
9/19/2003 | CV | New Issue: Merrill prices $44 million 0% notes linked to Pfizer
|
8/25/2003 | CV | New Issue: UBS prices $4.68 million 0% notes linked to Pfizer
|